UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2021

Commission File Number: 001-38781

 

 

HEXO Corp.

(Translation of registrant’s name into English)

 

 

3000 Solandt Road

Ottawa, Ontario, Canada K2K 2X2

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☐            Form 40-F  ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

EXPLANATORY NOTE

Exhibit 99.1 included with this Report on Form 6-K is hereby incorporated by reference into (i) the Registration Statement on Form F-10 of HEXO Corp. and HEXO Operations Inc. (File No. 333-256131), and (ii) the Registration Statement on Form F-10 of HEXO Corp. (File No. 333-255264).

 

Exhibit

  

Description

99.1    Amended and restated material change report dated July 14, 2021


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    HEXO Corp.
Date: July 14, 2021     /s/ Trent MacDonald
    Chief Financial Officer

Exhibit 99.1

FORM 51-102F3

AMENDED AND RESTATED MATERIAL CHANGE REPORT

 

1.

Name and Address of Company

HEXO Corp. (the “Company” or “HEXO”)

3000 Solandt Road

Ottawa, Ontario K2K 2X2

 

2.

Date of Material Change

May 28, 2021 (as updated on July 14, 2021 only for new financial information having been made available)

 

3.

News Release

A first news release dated May 28, 2021 was disseminated through the facilities of GlobeNewswire and was filed on the System for Electronic Document Analysis and Retrieval (“SEDAR”). A copy of the news release is available under the Company’s profile on SEDAR at www.sedar.com.

A subsequent news release dated July 14, 2021 was disseminated through the facilities of GlobeNewswire and was filed on the System for Electronic Document Analysis and Retrieval (“SEDAR”). A copy of the news release is available under the Company’s profile on SEDAR at www.sedar.com and is attached as Schedule A hereto.

 

4.

Summary of Material Change

On May 28, 2021, the Company entered into a definitive share purchase agreement (the “Share Purchase Agreement”) to acquire all of the outstanding shares of the entities that carry on the business of Redecan, for a purchase price of $925 million payable in cash and common shares of HEXO, subject to certain customary adjustments (the “Transaction”).

On July 14, 2021, the Company announced and made publicly available certain previously unavailable historical audited annual and interim unaudited financial statements of 2579951 Canada Inc. (being the entity, together with its subsidiaries, carrying on the business of Redecan) (collectively, “Redecan”) as well as certain pro forma financial statements in connection with the Transaction.

This material change report is being filed to supplement the information provided in the Company’s material change report dated June 4, 2021 with this financial information that was not available on June 4, 2021. By its filing, this material change report is incorporated into and forms part of each of the Company’s (Equity) Amended and Restated Short Form Base Shelf Prospectus dated May 25, 2021 (as well as, for greater certainty, the Company’s Prospectus Supplement dated May 11, 2021 filed pursuant to the aforementioned Amended and Restated Short Form Base Shelf Prospectus) and the Company’s (Debt) Short Form Base Shelf Prospectus dated May 21, 2021.


5.

Full Description of Material Change

The Company entered into the Share Purchase Agreement to acquire all of the outstanding shares of the entities that carry on the business of Redecan, Canada’s largest privately-owned licensed producer, for a purchase price of $925 million payable in cash and common shares of HEXO, subject to certain customary adjustments.

Under the terms of the Share Purchase Agreement, the $925 million purchase price will be paid to the Redecan shareholders as follows:

 

   

$400 million of consideration due on closing paid in cash; and

 

   

$525 million of consideration due on closing paid through the issuance of HEXO common shares (the “Consideration Shares”) at an implied price per share of $7.53.

The $7.53 price per Consideration Share represents the five trading day-period volume-weighted average price (VWAP) of HEXO common shares on the Toronto Stock Exchange (“TSX“) as of the close of Canadian markets on May 27, 2021. It is anticipated that the Redecan shareholders will collectively hold approximately 31% of HEXO’s issued and outstanding common shares immediately following the closing of the Transaction on a pro forma non-diluted basis. Under TSX rules, the Transaction requires a simple majority approval of HEXO’s shareholders. HEXO expects to convene a meeting of shareholders to be held in August 2021 for the purpose of submitting the Transaction to shareholders for approval.

HEXO announced on May 27, 2021, the closing of an offering of US$360,000,000 aggregate principal amount of senior secured convertible notes due May 1, 2023 (the “Notes”) directly to an institutional purchaser and certain of its affiliates or related funds. HEXO will use substantially all of the net proceeds from the sale of the Notes to satisfy the anticipated cash portion of the purchase price in the Transaction.

In addition to restrictions under applicable securities laws, resale by the Redecan shareholders of the Consideration Shares will be restricted by a 24-month hold period during which, subject to certain exceptions, each Redecan shareholder will be entitled to sell a maximum of 1/24th of the initial amount of such Redecan shareholder’s Consideration Shares issued under the Transaction. Furthermore, the Redecan shareholders have agreed to be bound by customary standstill provisions for an 18-month period, during which such shareholders have agreed to support HEXO’s management and board of directors.

The Share Purchase Agreement provides for expense reimbursement provisions in favour of the Redecan shareholders if the Transaction is terminated by either party in certain specified circumstances.

Redecan shareholders will receive the right to nominate up to two members to HEXO’s board of directors (within certain parameters) and will be entitled to other customary governance rights, including limited demand and piggyback registration rights, pursuant to an investor rights agreement (the “Investor Rights Agreement”). Following closing of the Transaction, HEXO’s board of directors will be increased to 10 members, with Peter James Montour and William Montour, two of Redecan’s founding shareholders, joining the HEXO board as directors. The Redecan shareholders will also be bound by customary non-competition and non-solicitation covenants in favour of HEXO and Redecan following the closing of the Transaction.

 

- 2 -


The Transaction is expected to close in calendar Q3 2021, subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals, including the approvals of the TSX and the New York Stock Exchange, and the shareholder approval described above required under TSX rules.

The Transaction was unanimously approved by HEXO’s board of directors.

Further information regarding the Transaction will be included in the information circular that HEXO will prepare, file, and mail in due course to its shareholders in connection with the meeting of shareholders to be held to consider the issuance of the Consideration Shares under the Transaction as required by TSX rules. The Share Purchase Agreement and Investor Rights Agreement will be filed under the SEDAR profile of HEXO on the SEDAR website at www.sedar.com.

On July 14, 2021, the Company announced and made publicly available certain previously unavailable historical audited annual and interim unaudited financial statements of Redecan as well as certain pro forma financial statements in connection with the Transaction. These financial statements were not available at the time the original Material Change Report dated June 4, 2021 was filed and only became available before the issuance of the Company’s press release on July 14, 2021.

The following financial statements set out in the schedules hereto form an integral part of this Amended and Restated Material Change Report:

 

  Schedule B:    Audited Consolidated Financial Statements of 2579951 Canada Inc. for the financial year ended December 31, 2020 (prepared in accordance with Canadian accounting standards for private enterprises (“ASPE”)
  Schedule C:    Unaudited Interim Consolidated Financial Statements of 2579951 Canada Inc. for the three months ended March 31, 2021 (prepared in accordance with ASPE)
  Schedule D:    Unaudited pro forma condensed consolidated financial statements of HEXO that give effect to the acquisition of Redecan as at April 30, 2021 and for the nine months ended April 30, 2021 and for the year ended July 31, 2020

 

6.

Reliance on Section 7.1(2) of National Instrument 51-102

Not Applicable.

 

7.

Omitted Information

Not Applicable.

 

- 3 -


8.

Executive Officer

The name and business number of the executive officer of the Company who is knowledgeable about the material change and this report is:

Sébastien St-Louis, President and Chief Executive Officer

1-866-438-8429

invest@HEXO.com

 

9.

Date of Report

July 14, 2021

 

- 4 -


SCHEDULE A

(See attached)


LOGO

HEXO provides update on Redecan acquisition

July 14, 2021 06:31 ET | Source: HEXO Corp.

OTTAWA, July 14, 2021 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NYSE: HEXO) is pleased to announce, that in connection with its previously announced acquisition of the entities operating the business of Redecan, it has now obtained and will be shortly filing the recently completed audited consolidated financial statements of Redecan for the financial year ended December 31, 2020 (“FY20”) and the unaudited interim financial statements for the first quarter ended March 31, 2021 (“1Q21”) prepared in accordance with Accounting standards for private enterprises (“ASPE”). The Company previously announced a definitive share purchase agreement to acquire Redecan, Canada’s largest privately-owned licensed producer.

“Redecan has the top consumer loyalty in Canada, impressive market share and leading products in key categories. Today, we are excited to finally share additional financial information with HEXO shareholders,” said HEXO CEO and co-founder Sebastien St-Louis. “Redecan’s historical financial statements demonstrate exactly what we already knew: Redecan is one of the fastest growth LPs in Canada with positive income from operations, impressive margins, lean operational efficiency and strong revenue. Once closed, the acquisition will further strengthen our position as a leader in the Canadian cannabis industry, bolster the Company as we look towards becoming a top three global cannabis products company and put us firmly on the path towards positive EPS.”

Key Financial Highlights (as per ASPE unless otherwise stated):

 

   

Revenue, net of excise duties of $73.6M for F20 and $24.7 million in Q1 F21, representing an increase of 146% over Q1 F20

 

   

Unadjusted EBITDA of $28.9M for F20 and $12.4M for Q1 F21, per the following reconciliation:

 

     Q1 F21      F20  

Net Earnings

     6,913,624        11,624,161  

Add back:

     

Amortization

     4,216,528        12,174,795  

Impairment loss on property, plant and equipment

     37,235        588,593  

Provision for income taxes

     1,230,000        4,499,595  

Unadjusted EBITDA

     12,397,387        28,887,144  

 

   

Income from operations of $8.3M and net earnings of $6.9M in Q1 F21.

 

   

Income from operations of $16.7M and net earnings of $11.6 million in F20.


   

Gross margins (gross margin divided by revenue, net of excise duties) of 51% in F20 and 58% in Q1 F21.

 

   

Selling, general and administrative costs, (defined as General and administrative, plus marketing and promotion, plus research and development) as a % of sales of 27% in F20 and 23% in Q1 F21.

 

   

Depreciable capital base, consisting of property, plant and equipment, was $84.1M at December 31, 2020, the lowest of any of the top 6 licensed producers in Canada.

Proforma Highlights for the Nine Months ended April 30, 2021 for HEXO Corp and the Nine Months ended March 31, 2021 for Redecan, adjusted to International Financial Reporting Standards (IFRS)*:

 

   

Net revenue of $155.6M.

 

   

Gross margin before fair value adjustments of $69.1M, or 44.4%.

 

   

Income from operations of $38.6M.

The Redecan acquisition is expected to close in calendar Q3 2021, subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals and the shareholder approval described above required under TSX rules.

Redecan’s historical financial statements for the financial year ended December 31, 2020 and for the first quarter ended March 31, 2021 as well as certain pro forma financial statements giving effect to the acquisition of Redecan by HEXO have been filed or furnished, as applicable, as schedules to an amended and restated material change report dated July 14, 2021 available under the Company’s profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov respectively.

About HEXO

HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, UP Cannabis, Original Stash, Bake Sale, Namaste, and REUP brands, and the medical market in Canada, Israel and Malta. The Company also serves the Colorado market through its Powered by HEXO® strategy and Truss CBD USA, a joint-venture with Molson Coors. In the event that the previously announced transactions to acquire 48North and Redecan close, HEXO expects to be the number one cannabis products company in Canada by recreational market share.

For more information, please visit www.hexocorp.com.

 

*

The Company’s unaudited pro forma condensed consolidated statement of financial position as of April 30, 2021 and the unaudited pro forma condensed consolidated statements of net earnings (loss) for the nine months ended April 30, 2021 and the year ended July 31, 2020 have been prepared by management of HEXO for the purpose of presenting the impact of the Acquisition, as described therein. Although the Acquisition had not closed as of the date of the pro forma financial statements, the unaudited pro forma condensed consolidated statement of financial position includes the effect of the Acquisition as if it had occurred on April 30, 2021. The unaudited pro forma condensed consolidated statement of net earnings (loss) for the nine months ended April 30, 2021 and the year ended July 31, 2020 give effect to the Acquisition as if it had occurred on August 1, 2019.

The unaudited pro forma condensed consolidated financial statements, including the notes thereto, should be read in conjunction with HEXO’s historical financial statements, and respective Management’s Discussion and Analysis of financial condition and results of operations as filed with or furnished to, as applicable, the Canadian and U.S. securities regulatory authorities and Redecan’s historical financial statements. The unaudited pro forma condensed consolidated financial statements are based on


assumptions and adjustments that are described in the notes to such pro forma financial statements The unaudited pro forma condensed consolidated financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the Acquisition. The unaudited pro forma condensed consolidated financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of operations in future periods or the results that actually would have been realized if HEXO and the acquired company (being the Redecan Group) had been a consolidated company during the specified periods. The application of the acquisition method of accounting depends on certain valuations and other studies that have yet to be completed. Accordingly, the pro forma adjustments are preliminary, subject to further revisions as additional information becomes available and additional analyses are performed and have been made solely for the purposes of providing unaudited pro forma condensed consolidated financial statements. Differences between these preliminary estimates and the final acquisition accounting will occur and these differences could have a material impact on the accompanying unaudited pro forma condensed consolidated financial statements and the consolidated company’s future earnings and financial position. Further, differences between the preliminary and final amounts will likely occur as a result of changes in the fair value of HEXO’s common shares to determine the actual purchase consideration for the Acquisition, as well as the actual amount of cash used in Redecan’s operations, and other changes in assets and liabilities.

Non-IFRS/Non-ASPE Measures

In this press release, reference is made to unadjusted EBITDA, which is not a measure of financial performance under International Financial Reporting Standards (IFRS) or Accounting Standards for Private Enterprises (ASPE). This metric and measure is not a recognized measure under IFRS or ASPE, does not have meanings prescribed under IFRS or ASPE and is as a result unlikely to be comparable to similar measures presented by other companies. This measure is provided as information complementary to those IFRS and ASPE measures by providing a further understanding of HEXO and Redecan’s operating results from the perspective of management. As such, this measure should not be considered in isolation or in lieu of a review of HEXO and Redecan’s financial information reported under IFRS or ASPE respectively.

Forward Looking Statements

This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are based on certain expectations and assumptions and are subject to known and unknown risks and uncertainties and other factors that could cause actual events, results, performance and achievements to differ materially from those anticipated in these forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

Investor Relations:

invest@HEXO.com

www.hexocorp.com

Media Relations:

(819) 317-0526

media@hexo.com


SCHEDULE B

(See attached)


2579951 Ontario Inc.

Consolidated Financial Statements

December 31, 2020


2579951 Ontario Inc.

Contents

For the year ended December 31, 2020

 

     Page  

Independent Auditor’s Report

  

Consolidated Financial Statements

  

Consolidated Balance Sheet

     1  

Consolidated Statement of Earnings (Loss)

     2  

Consolidated Statement of Retained Earnings (Deficit)

     3  

Consolidated Statement of Cash Flows

     4  

Notes to the Consolidated Financial Statements

     5  


 

LOGO

Independent Auditor’s Report

To the Shareholders of 2579951 Ontario Inc.:

Opinions

We have audited the consolidated financial statements of 2579951 Ontario Inc. and its subsidiaries (the “Company”), which comprise the consolidated balance sheet as at December 31, 2020, and the consolidated statements of earnings (loss), retained earnings (deficit) and cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

Unmodified Opinion on the Consolidated Financial Position

In our opinion, the accompanying consolidated balance sheet presents fairly, in all material respects, the consolidated financial position of the Company as at December 31, 2020, in accordance with Canadian accounting standards for private enterprises.

Qualified Opinion on the Consolidated Results of Operations and Cash Flows

In our opinion, except for the possible effects of the matter described in the Basis for Opinions, Including Basis for Qualified Opinion on the Results of Consolidated Operations and Cash Flows section or our report, the accompanying consolidated statement of earnings (loss), retained earnings (deficit) and cash flows present fairly, in all material respects, the consolidated results of operations and cash flows of the Company for the year ended December 31, 2020 in accordance with Canadian accounting standards for private enterprises.

Basis for Opinions, Including Basis for Qualified Opinion on the Results of Consolidated Operations and Cash Flows

We were appointed as auditors of the Company after December 31, 2020 and, therefore, did not observe the counting of physical inventories at January 1, 2020 and were unable to satisfy ourselves concerning those inventory quantities by alternative means. Since opening inventories enter into the determination of the results of operations and cash flows, we were unable to determine whether any adjustments might have been required in the consolidated statement of earnings (loss) and the cash flows from operating activities reported in the cash flow statement. Our audit opinion on the consolidated results of operations and cash flows for the year ended December 31, 2020 is modified because of the possible effects of this scope limitation.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our unmodified opinion on the consolidated financial position and our qualified opinion on the consolidated results of operations and cash flows.

Other Matter - Comparative Information

The comparative information for the year ended December 31, 2019 is unaudited and accordingly we do not express an audit opinion on the comparative figures.


Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with Canadian accounting standards for private enterprises, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company’s financial reporting process.

Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

 

   

Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

 

   

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.

 

   

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

 

   

Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.

 

   

Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

 

  

LOGO

Burlington, Ontario    Chartered Professional Accountants
July 13, 2021    Licensed Public Accountants
   LOGO


2579951 Ontario Inc.

Consolidated Balance Sheet

As at December 31, 2020

 

     2020      2019  
            (Unaudited)  

Assets

     

Current

     

Cash

     7,806,974        3,110,116  

Trade receivables

     14,666,289        5,335,688  

Government remittances receivable

     2,200,906        7,948,282  

Inventory (Note 3)

     26,792,382        16,454,944  

Prepaid expenses and deposits

     3,213,503        1,296,368  

Receivable from shareholders (Note 4)

     117,906        —    
     54,797,960        34,145,398  

Property, plant and equipment (Note 5)

     84,136,530        65,322,854  

Deposits (Note 5)

     4,923,006        —    
     143,857,496        99,468,252  

Liabilities

     

Current

     

Trade and other payables

     9,407,837        9,815,603  

Government remittances payable

     3,030,819        876,569  

Income taxes payable

     4,374,595        104,199  

Advances from related parties (Note 6)

     116,215,958        89,467,755  
     133,029,209        100,264,126  

Shareholders’ Equity (Deficit)

     

Share capital (Note 7)

     48        48  

Retained earnings (deficit)

     10,828,239        (795,922
     10,828,287        (795,874
     143,857,496        99,468,252  

Approved on behalf of the Board

 

     

Director

     

The accompanying notes are an integral part of these consolidated financial statements

 

1


2579951 Ontario Inc.

Consolidated Statement of Earnings (Loss)

For the year ended December 31, 2020

 

     2020     2019  
           (Unaudited)  

Revenue

    

Revenue before returns and allowances

     107,295,969       17,337,454  

Returns and allowances

     (5,209,031     (152,289

Revenue before excise duties (Note 8)

     102,086,938       17,185,165  

Excise duties

     (28,437,696     (3,964,572

Revenue, net of excise duties

     73,649,242       13,220,593  

Cost of sales (Note 3)

     35,811,886       6,028,301  

Gross margin

     37,837,356       7,192,292  

Selling, general and administrative expenses

    

Advertising and promotion

     997,041       318,939  

Amortization

     1,303,945       1,021,593  

Business taxes and licences

     2,148,637       486,074  

Consulting fees

     1,316,135       —    

Donations

     —         2,339  

Freight and logistics

     1,850,686       284,236  

Insurance

     811,492       514,115  

Interest and bank charges

     147,755       88,711  

Meals and entertainment

     119,068       99,819  

Office and general

     1,903,554       488,603  

Professional fees

     260,936       173,557  

Property taxes

     101,340       64,185  

Rental

     151,873       191,450  

Repairs and maintenance

     1,122,879       270,627  

Salaries, wages and benefits

     6,188,585       2,420,380  

Supplies

     2,737,949       726,733  
     21,161,875       7,151,361  

Income from operations

     16,675,481       40,931  

Other income (loss)

    

Foreign exchange gain

     36,868       44,127  

Impairment loss on property, plant and equipment (Note 5)

     (588,593     —    
     (551,725     44,127  

Earnings before income tax

     16,123,756       85,058  

Provision for income taxes (Note 9)

     4,499,595       123,299  

Net earnings (loss)

     11,624,161       (38,241

The accompanying notes are an integral part of these consolidated financial statements

 

2


2579951 Ontario Inc.

Consolidated Statement of Retained Earnings (Deficit)

For the year ended December 31, 2020

 

     2020     2019  
           (Unaudited)  

Deficit, beginning of year

     (795,922     (757,681

Net earnings (loss)

     11,624,161       (38,241

Retained earnings (deficit), end of year

     10,828,239       (795,922

The accompanying notes are an integral part of these consolidated financial statements

 

3


2579951 Ontario Inc.

Consolidated Statement of Cash Flows

For the year ended December 31, 2020

 

     2020     2019  
           (Unaudited)  

Cash provided by (used for) the following activities

    

Operating activities

    

Net earnings (loss)

     11,624,161       (38,241

Amortization

     12,174,795       4,932,847  

Impairment loss on property, plant and equipment

     588,593       —    
     24,387,549       4,894,606  

Changes in working capital accounts

    

Trade receivables

     (9,330,601     (1,772,667

Government remittances receivable

     5,747,376       (3,900,635

Inventory

     (10,337,438     (11,624,220

Prepaid expenses and deposits

     (1,917,135     (478,835

Income taxes payable

     4,270,396       (582,372

Trade and other payables

     (407,765     5,392,385  

Government remittances payable

     2,154,250       221,408  
     14,566,632       (7,850,330

Financing activity

    

Advances from related parties

     26,748,203       40,452,298  

Investing activities

    

Purchases of property, plant and equipment

     (31,577,065     (33,668,113

Advances to shareholders

     (117,906     —    

Deposits

     (4,923,006     —    

Increase (decrease) in cash

     4,696,858       (1,066,145

Cash, beginning of year

     3,110,116       4,176,261  

Cash, end of year

     7,806,974       3,110,116  

The accompanying notes are an integral part of these consolidated financial statements

 

4


2579951 Ontario Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2020

(Figures as at December 31, 2019 and for the year then ended are unaudited)

 

1.

Incorporation and operations

2579951 Ontario Inc. was incorporated under the Ontario Business Corporations Act on May 30, 2017. 2579951 Ontario Inc., through its wholly owned subsidiaries 9037136 Canada Inc. (o/a Redecan Pharm) and 2526356 Ontario Inc. (collectively referred to as the “Company”), operate as a licensed cultivator, processor and seller of medical and recreational cannabis in Canada under the Cannabis Act.

 

2.

Significant accounting policies

The consolidated financial statements have been prepared in accordance with Canadian accounting standards for private enterprises “ASPE” set out in Part II of the CPA Canada Handbook - Accounting, as issued by the Accounting Standards Board in Canada and include the following significant accounting policies:

Basis of consolidation

The Company consolidates all subsidiaries. As such, assets, liabilities, revenues and expenses of all subsidiaries have been consolidated and all inter company transactions and balances have been eliminated.

Inventory

Inventory includes biological assets (growing cannabis plants), agriculture inventories (harvested cannabis) and related supplies and packaging materials. All inventory is valued at the lower of cost and net realizable value. Cost is determined by the weighted average method, and includes purchase price of direct materials, direct labour and an allocation of certain overheads. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and selling costs.

Property, plant and equipment

Property, plant and equipment are initially recorded at cost. Amortization is provided using the declining balance method at rates intended to amortize the cost of assets over their estimated useful lives.

 

     Method      Rate  

Land and land improvements

     Not amortized     

Buildings

     declining balance        10

Automotive

     declining balance        30

Computer equipment

     declining balance        67

Computer software

     declining balance        100

Equipment

     declining balance        30

Fences

     declining balance        10

Furniture and fixtures

     declining balance        20

Office equipment

     declining balance        20

Machinery and equipment

     declining balance        30

Property, plant and equipment acquired during the year but not placed into use during this time are not amortized in the year of acquisition.

Revenue recognition

Revenue from the sale of cannabis to customers is recognized when the Company transfers the control of the goods to the customer, which occurs upon delivery and acceptance by the customer. The Company recognizes revenue for the amount of consideration the Company expects to receive, taking into account the impact from any rights of return on sales, price concessions or similar obligations.

Income taxes

The Company accounts for income taxes using the taxes payable method. Under this method, a provision is only made for taxes payable or recoverable in the current year. Income taxes payable/recoverable are measured using the income tax rates and laws established by taxation authorities and in effect at the balance sheet date.

 

5


2579951 Ontario Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2020

(Figures as at December 31, 2019 and for the year then ended are unaudited)

 

2.

Significant accounting policies (Continued from previous page)

Leases

A lease that transfers substantially all of the benefits and risks of ownership is classified as a capital lease. At the inception of a capital lease, an asset and a payment obligation is recorded at an amount equal to the lesser of the present value of the minimum lease payments and the property’s fair market value. Assets under capital leases are amortized using the declining balance method, over their estimated useful lives. All other leases are accounted for as operating leases and rental payments are expensed as incurred.

An arrangement contains a lease where the arrangement conveys a right to use the underlying tangible asset, and whereby its fulfillment is dependent on the use of the specific tangible asset. After the inception of the arrangement, a reassessment of whether the arrangement contains a lease is made only in the event that:

  -

there is a change in contractual terms;

  -

a renewal option is exercised or an extension is agreed upon by the parties to the arrangement;

  -

there is a change in the determination of whether the fulfillment of the arrangement is dependent on the use of the specific tangible asset; or

  -

there is a substantial physical change to the specified tangible asset.

Foreign currency translation

These consolidated financial statements have been presented in Canadian dollars, the principal currency of the Company’s operations.

Transaction amounts denominated in foreign currencies are translated into their Canadian dollar equivalents at exchange rates prevailing at the transaction dates. Carrying values of monetary assets and liabilities reflect the exchange rates at the balance sheet date. Gains and losses on translation or settlement are included in the determination of net earnings (loss) for the current year.

Long-lived assets and discontinued operations

Long-lived assets consist of property, plant and equipment. Long-lived assets held for use are measured and amortized as described in the applicable accounting policies.

The Company performs impairment testing on long-lived assets held for use whenever events or changes in circumstances indicate that the carrying amount of an asset, or group of assets, may not be recoverable. The carrying amount of a long-lived asset is not recoverable if the carrying amount exceeds the sum of the undiscounted future cash flows from its use and disposal. If the carrying amount is not recoverable, impairment is then measured as the amount by which the asset’s carrying amount exceeds its fair value. Fair value is measured using discounted future cash flows. Any impairment is included in net earnings (loss) for the year.

Use of estimates

The preparation of consolidated financial statements in conformity with Canadian accounting standards for private enterprises requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the year.

Accounts receivable are stated after evaluation as to their collectability and an appropriate allowance for doubtful accounts is provided where considered necessary. Provisions are made for slow moving and obsolete inventory, and for potential returns, allowance and price concessions on product sold. Amortization is based on the estimated useful lives of property, plant and equipment.

By their nature, these estimates are subject to measurement uncertainty, and the effect on the consolidated financial statements from changes in such estimates in future years could be material. These estimates and assumptions are reviewed periodically and, as adjustments become necessary they are reported in earnings in the years in which they become known.

 

6


2579951 Ontario Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2020

(Figures as at December 31, 2019 and for the year then ended are unaudited)

 

2.

Significant accounting policies (Continued from previous page)

Financial instruments

The Company recognizes its financial instruments when the Company becomes party to the contractual provisions of the financial instrument. All financial instruments are initially recorded at their fair value, including financial assets and liabilities originated and issued in a related party transaction with management. Financial assets and liabilities originated and issued in all other related party transactions are initially measured at their carrying or exchange amount in accordance with Section 3840 Related Party Transactions.

At initial recognition, the Company may irrevocably elect to subsequently measure any financial instrument at fair value. The Company has not made such an election during the year.

Transaction costs and financing fees directly attributable to the origination, acquisition, issuance or assumption of financial instruments subsequently measured at fair value are immediately recognized in net earnings (loss). Conversely, transaction costs and financing fees are added to the carrying amount for those financial instruments subsequently measured at cost or amortized cost.

 

3.

Inventory

 

     2020      2019  

Packaging materials

     4,571,980        4,586,233  

Cannabis plants

     1,833,898        1,830,474  

Bulk cannabis flower

     12,489,460        5,385,895  

Bulk cannabis extracts

     3,218,154        3,383,898  

Finished goods

     4,678,890        1,268,444  
     26,792,382        16,454,944  

The cost of inventories recognized as an expense and included in cost of sales amounted to $35,811,886 (2019 – $6,028,301), including $661,624 (2019 - $nil) relating to packaging materials which were written off as obsolete during the year. Included in cost of sales is amortization of production equipment of $10,042,552 (2019 - $3,911,254).

 

4.

Receivable from shareholder

The balance due from the shareholder is unsecured, non-interest bearing and due on demand.

 

7


2579951 Ontario Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2020

(Figures as at December 31, 2019 and for the year then ended are unaudited)

 

5.

Property, plant and equipment

 

                   2020      2019  
            Accumulated      Net book      Net book  
     Cost      amortization      value      value  

Land and land improvements

     5,337,750        —          5,337,750        2,984,120  

Buildings

     59,647,615        7,541,462        52,106,153        46,173,589  

Automotive

     215,204        87,368        127,836        109,017  

Computer equipment

     1,766,038        1,340,614        425,424        560,231  

Computer software

     4,069,098        3,590,025        479,073        1,424,915  

Equipment

     33,040,257        7,850,969        25,189,288        13,599,584  

Fences

     21,187        10,875        10,312        11,410  

Furniture and fixtures

     316,282        68,881        247,401        261,242  

Office equipment

     151,511        37,095        114,416        70,300  

Machinery and equipment

     253,235        154,358        98,877        128,446  
     104,818,177        20,681,647        84,136,530        65,322,854  

Deposits included in the consolidated balance sheet represent deposits placed for certain property, plant and equipment to be used in the Company’s production operations, which has not been delivered as of December 31, 2020. Additional commitments relating to these items is disclosed in Note 10.

During the year the Company recorded an impairment loss on property, plant and equipment relating to certain construction costs which had been capitalized, but for which management determined the construction was not expected to be completed.

 

6.

Advances from related parties

 

     2020      2019  

2516576 Ontario Inc. (controlling shareholder)

     115,847,648        89,132,156  

Minority shareholders

     1,060        75,779  

Member of immediate family of minority shareholders

     367,250        259,820  
     116,215,958        89,467,755  

Amounts owing to the above related parties are unsecured, non-interest bearing and due on demand.

 

7.

Share capital

Authorized

 

 

Unlimited number of common shares    2020      2019  

Issued

     

100 Common shares

     48        48  

 

8


2579951 Ontario Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2020

(Figures as at December 31, 2019 and for the year then ended are unaudited)

 

8.

Revenue

The Company earns revenues from sales to medical patients (“medical”) and through provincial distributors for the recreational market (“recreational”). The gross revenue recognized by major category is as follows:

 

     2020      2019  

Revenue

     

Medical

     5,499,766        2,204,971  

Recreational

     101,796,203        15,132,483  

Returns and allowances

     (5,209,031      (152,289

Revenue before excise taxes

     102,086,938        17,185,165  

 

9.

Income taxes

The reconciliation of the Company’s effective income tax expense is as follows:

 

     2020      2019  

Expected tax expense

     4,272,795        (10,134

Increase (decrease) in income tax expense resulting from:

     

Impact of difference between amortization for accounting purposes and CCA taken in the period

     (1,077,586      (1,050,024

Intercompany charges capitalized for tax purposes

     4,163,664        (1,734,670

Ontario minimum tax

     214,109        —    

Non-deductible expenses

     19,485        13,089  

Impact of tax loss carried forward against period taxable income

     (3,092,872      2,905,038  

Actual tax expense

     4,499,595        123,299  

 

10.

Commitments

The Company has entered into various operating lease agreements with estimated minimum annual payments as follows:

 

2021

     214,243  

2022

     210,000  

2023

     210,000  

2024

     210,000  

2025

     210,000  

Thereafter, to 2029

     390,000  
     1,444,243  

During the year, the Company signed various agreement to purchase items of manufacturing equipment. As at December 31, 2020, outstanding commitments for manufacturing equipment were $16,349,578.

 

11.

Financial instruments

The Company, as part of its operations, carries a number of financial instruments. It is management’s opinion that the Company is not exposed to significant interest, currency, credit, liquidity or other price risks arising from these financial instruments except as otherwise disclosed.

 

9


2579951 Ontario Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2020

(Figures as at December 31, 2019 and for the year then ended are unaudited)

Credit concentration

As at December 31, 2020, 3 customers (2019 – 3) accounted for 95% (2019 – 89%) of consolidated revenues before excise duties and 3 customers (2019 – 3) accounted for 97% (2019 – 99%) of the consolidated accounts receivable. The Company believes that there is no unusual exposure associated with the collection of these receivables as the customers are government agencies that distribute cannabis in their respective provinces.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company’s objective is to have sufficient liquidity to meet its liabilities from due. The Company monitors cash balances and cash flows generated from operations to meet its requirements. The Company is exposed to liquidity risk relating to its trade and other payables and advances from related parties which are due on demand.

 

12.

Subsequent events

On May 28, 2021, HEXO Corp. announced that it has entered into a definitive share purchase agreement to acquire all the outstanding shares of the Company for a purchase price of $925 million payable in cash and through the issuance of common shares of HEXO Corp. (the “Transaction”). The Transaction is subject to certain customary adjustments, closing conditions, applicable regulatory approvals, and HEXO Corp. shareholder approval. The close date of the Transaction is not determinable as of the date of these financial statements. As part of the Transaction and related customary adjustments, the parties have agreed that the balance owing to the controlling shareholder 2516576 Ontario Inc., as disclosed in Note 6, will be settled in full on close of the Transaction. Accordingly, the balance owing to 2516576 Ontario Inc. has been classified as a current liability in advances from related parties in the consolidated balance sheet.

On May 14, 2021, 2579951 Ontario Inc. was amalgamated with its parent company, 2516576 Ontario Inc., to form 5048963 Ontario Inc. (the “Company”).

 

13.

ASPE to International Financial Reporting Standards Reconciliation

As discussed in Note 12, the Company entered into a definitive share purchase agreement on May 28, 2021 to sell all of the outstanding shares of the Company to HEXO Corp. The Company has presented an ASPE to International Financial Reporting Standards (“IFRS”) reconciliation for the statement of earnings (loss), balance sheet and a description of the impact of each adjustment for each period presented. The tables below quantify the significant differences on the Company’s net earnings and financial position between ASPE and IFRS as at and for the years ended December 31, 2020 and 2019 with descriptions thereto of such differences.

 

     Notes      2020      2019  

Net income (loss) after tax under ASPE

        11,624,161        (38,241

IFRS Adjustments

        

Variable consideration adjustment to gross revenue

     (i)        (249,883      (112,725

Realized fair value amounts on inventory sold

     (ii)        (81,213,167      (6,013,788

Unrealized gain on biological asset transformation

     (ii)        122,236,824        18,933,426  

Reversal of cost of sales

     (iii)        100,000        75,000  

Depreciation on right-of-use assets

     (iii)        (249,293      (198,245

Interest expense on lease liability

     (iii)        (147,696      (146,046

Reversal of rent expense

     (iii)        149,388        189,554  

Deferred income tax expense

     (iv)        (10,619,186      (3,956,264

Net and comprehensive income under IFRS

        41,631,148        8,732,671  

 

10


13.

ASPE to International Financial Reporting Standards Reconciliation (Continued from previous page)

 

     Notes      As reported
under ASPE
     Adjustments      As reported
under IFRS
 

As at December 31, 2020

           

Inventory

     (ii)        26,792,382        49,309,456        76,101,838  

Biological assets

     (ii)        —          9,098,703        9,098,703  

Right-of-use asset, net

     (iii)        —          1,737,168        1,737,168  

Trade and other payables

     (iii)        9,407,837        (120,000      9,287,837  

Current lease liability

     (iii)        —          238,650        238,650  

Non-current lease liability

     (iii)        —          2,001,156        2,001,156  

Provisions

     (i), (iii)        —          405,071        405,071  

Deferred tax liability

     (iv)        —          14,575,450        14,575,450  

Retained earnings

     (i), (ii), (iii), (iv)        10,828,239        43,045,000        53,873,239  

As at December 31, 2019

           

Inventory

     (ii)        16,454,944        11,714,981        28,169,925  

Biological assets

     (ii)        —          5,669,521        5,669,521  

Right-of-use asset, net

     (iii)        —          1,986,461        1,986,461  

Trade and other payables

     (iii)        9,815,603        (60,000      9,755,603  

Current lease liability

     (iii)        —          249,387        249,387  

Non-current lease liability

     (iii)        —          2,032,112        2,032,112  

Provision

     (i), (iii)        —          155,188        155,188  

Deferred tax liability

     (iv)        —          3,956,264        3,956,264  

Retained earnings

     (i), (ii), (iii), (iv)        (795,922      13,038,012        12,242,090  

(i) Under IFRS, an adjustment is required to record the constraint on variable consideration resulting from the markdown / price reductions arrangements with customers.

(ii) Under IFRS, an adjustment is required to record biological assets at fair value less cost to sell. Further, biological assets are transferred to inventory at fair value less cost to sell. An adjustment is made to recognize inventory at cost which is the fair value less cost of sell at the point where it transferred from biological assets. The following represent the key assumptions used in the determination of the fair value of the biological assets:

Weighted average selling price (per gram) - $3.18 (2019 - $3.31)

Yield per plant (dried bud and trim) - 1,144 grams (2019 - 968 grams)

Stage of growth - 43% (2019 - 53%)

Attrition rate - 1% (2019 - 1%)

(iii) Under IFRS, an adjustment is required to record right-of-use assets and lease liabilities for items leased. After initial recognition, IFRS requires the discounted lease liability to be accreted to the full liability amount and associated interest expense is recognized. In preparing the estimate for the value of the lease liability, management has determined a range of incremental borrowing rates attributable to underlying leases to be 2.28% - 6.84%. Depreciation expense is recognized on the right-of use assets over the lease term or the non-cancellable lease term ranging from 2 - 21 years. Additionally, an adjustment for lease restitution costs is also required to be recognized under IFRS as a provision.

(iv) Under ASPE, the Company uses the taxes payable method of accounting for income taxes. Under IFRS, the Company is required to recognize both current and deferred taxes. Deferred tax has been recognized on any temporary differences between the carrying amounts of assets and liabilities and the corresponding tax bases used in the computation of taxable earnings. Deferred tax assets and liabilities have been measured at the tax rates that are expected to apply in the period when the asset is realized, and the liability is settled. Deferred tax assets are recognized to the extent future recovery is probable. Deferred tax assets have been reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.


SCHEDULE C

(See attached)


2579951 Ontario Inc.

Interim Consolidated Financial Statements

March 31, 2021

(Unaudited)

 

- 1 -


2579951 Ontario Inc.

Contents

For the 3 month periods ended March 31, 2021 and 2020

(Unaudited)

 

     Page  

Interim Consolidated Financial Statements

  

Interim Consolidated Balance Sheets

     1  

Interim Consolidated Statements of Earnings (Loss)

     2  

Interim Consolidated Statements of Retained Earnings (Deficit)

     3  

Interim Consolidated Statements of Cash Flows

     4  

Notes to the Interim Consolidated Financial Statements

     5  


2579951 Ontario Inc.

Interim Consolidated Balance Sheets

As at

(Unaudited)

 

     March 31
2021
     December 31
2020
 
            (audited)  

Assets

     

Current

     

Cash

     2,811,611        7,806,974  

Trade receivables

     14,708,430        14,666,289  

Government remittances receivable

     1,533,359        2,200,906  

Inventory (Note 3)

     31,306,782        26,792,382  

Prepaid expenses and deposits

     5,655,733        3,213,503  

Receivable from shareholders (Note 4)

     117,937        117,906  
     56,133,852        54,797,960  

Property, plant and equipment (Note 5)

     85,481,713        84,136,530  

Deposits (Note 5)

     4,795,656        4,923,006  
     146,411,221        143,857,496  

Liabilities

     

Current

     

Trade and other payables

     6,172,256        9,407,837  

Government remittances payable

     2,657,052        3,030,819  

Income taxes payable

     3,604,994        4,374,595  

Advances from related parties (Note 6)

     116,235,008        116,215,958  
     128,669,310        133,029,209  

Share capital (Note 7)

     48        48  

Retained earnings

     17,741,863        10,828,239  
     17,741,911        10,828,287  
     146,411,221        143,857,496  

Approved on behalf of the Board

 

     

Director

     

The accompanying notes are an integral part of these financial statements

 

1


2579951 Ontario Inc.

Interim Consolidated Statements of Earnings (Loss)

For the periods ended March 31, 2021 and March 31, 2020

(Unaudited)

 

     3 Months
Ended
    3 Months
Ended
 
     March 31     March 31  
     2021     2020  

Revenue

    

Revenue before returns and allowances

     35,038,368       13,051,200  

Returns and allowances

     (1,121,304     (56,925

Revenue before excise duties (Note 8)

     33,917,064       12,994,275  

Excise duties

     (9,265,410     (2,980,950

Revenue, net of excise duties

     24,651,654       10,013,325  

Cost of sales (Note 3)

     10,279,719       8,228,063  

Gross margin

     14,371,935       1,785,262  

Selling, general and administrative expenses

    

Advertising and promotion

     727,064       12,320  

Amortization

     378,648       325,322  

Business taxes and licences

     673,270       278,256  

Consulting fees

     142,408       487,309  

Freight and logistics

     680,598       201,113  

Insurance

     275,996       151,755  

Interest and bank charges

     42,951       32,276  

Meals and entertainment

     25,422       31,096  

Office and general

     513,326       272,213  

Professional fees

     15,903       32,555  

Property taxes

     53,567       24,477  

Repairs and maintenance

     258,847       143,786  

Rental

     37,397       38,289  

Salaries, wages and benefits

     1,403,717       883,467  

Supplies

     831,534       579,187  
     6,060,648       3,493,421  

Income (loss) from operations

     8,311,287       (1,708,159

Other income (loss)

    

Foreign exchange gain (loss)

     (130,428     302,253  

Impairment loss on property, plant and equipment

     (37,235     —    
     (167,663     302,253  

Earnings (loss) before income tax

     8,143,624       (1,405,906

Provision for income taxes (Note 9)

     1,230,000       609,666  

Net earnings (loss)

     6,913,624       (2,015,572

The accompanying notes are an integral part of these financial statements

 

2


2579951 Ontario Inc.

Interim Consolidated Statements of Retained Earnings (Deficit)

For the periods ended March 31, 2021 and March 31, 2020

(Unaudited)

 

     3 Months
Ended
     3 Months
Ended
 
     March 31      March 31  
     2021      2020  

Retained earnings (deficit), beginning of period

     10,828,239        (795,921

Net earnings (loss)

     6,913,624        (2,015,572

Retained earnings (deficit), end of period

     17,741,863        (2,811,493

The accompanying notes are an integral part of these financial statements

 

3


2579951 Ontario Inc.

Interim Consolidated Statements of Cash Flows

For the periods ended March 31, 2021 and March 31, 2020

(Unaudited)

 

     3 Months
Ended
    3 Months
Ended
 
     March 31     March 31  
     2021     2020  

Cash provided by (used for) the following activities

    

Operating activities

    

Net earnings (loss)

     6,913,624       (2,015,572

Amortization

     4,261,528       2,034,043  

Impairment loss on property, plant and equipment

     37,235       —    
     11,212,387       18,471  

Changes in working capital accounts

    

Trade receivables

     (42,141     (5,519,189

Government remittances receivable

     667,547       (189,266

Inventory

     (4,514,399     (740,794

Prepaid expenses and deposits

     (2,442,230     (258,646

Trade and other payables

     (3,235,580     (2,175,960

Government remittances payable

     (373,767     41,413  

Income taxes payable

     (769,601     109,666  
     502,216       (8,714,305

Financing activity

    

Advances from related parties

     19,050       11,481,461  

Investing activities

    

Purchases of property, plant and equipment

     (5,643,948     (5,545,093

Advances to shareholders

     (31     —    

Deposits

     127,350       —    
     (5,516,629     (5,545,093

Decrease in cash

     (4,995,363     (2,777,937

Cash, beginning of period

     7,806,974       3,110,116  

Cash, end of period

     2,811,611       332,179  

The accompanying notes are an integral part of these financial statements

 

4


2579951 Ontario Inc.

Notes to the Interim Consolidated Financial Statements

For the periods ended March 31, 2021 and 2020

(Unaudited)

 

1.

Incorporation and operations

2579951 Ontario Inc. was incorporated under the Ontario Business Corporations Act on May 30, 2017. 2579951 Ontario Inc., through its wholly owned subsidiaries 9037136 Canada Inc. (o/a Redecan Pharm) and 2526356 Ontario Inc. (collectively referred to as the “Company”), operate as a licensed cultivator, processor and seller of medical and recreational cannabis in Canada under the Cannabis Act.

 

2.

Significant accounting policies

The interim consolidated financial statements have been prepared in accordance with Canadian accounting standards for private enterprises set out in Part II of the CPA Canada Handbook - Accounting, as issued by the Accounting Standards Board in Canada and include the following significant accounting policies:

Basis of consolidation

The Company consolidates all subsidiaries. As such, assets, liabilities, revenues and expenses of all subsidiaries have been consolidated and all inter company transactions and balances have been eliminated.

Inventory

Inventory includes biological assets (growing cannabis plants), agriculture inventories (harvested cannabis) and related supplies and packaging materials. All inventory is valued at the lower of cost and net realizable value. Cost is determined by the weighted average method, and includes purchase price of direct materials, direct labour and an allocation of certain overheads. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and selling costs.

Property, plant and equipment

Property, plant and equipment are initially recorded at cost. Amortization is provided using the declining balance method at rates intended to amortize the cost of assets over their estimated useful lives.

 

     Method      Rate  

Land and land improvement

     Not amortized     

Buildings

     declining balance        10

Automotive

     declining balance        30

Computer equipment

     declining balance        67

Computer software

     declining balance        100

Equipment

     declining balance        30

Fences

     declining balance        10

Furniture and fixtures

     declining balance        20

Office equipment

     declining balance        20

Machinery and equipment

     declining balance        30

Property, plant and equipment acquired during the period but not placed into use during this time are not amortized in the period of acquisition.

Revenue recognition

Revenue from the sale of cannabis to customers is recognized when the Company transfers the control of the goods to the customer, which occurs upon delivery and acceptance by the customer. The Company recognizes revenue for the amount of consideration the Company expects to receive, taking into account the impact from any rights of return on sales, price concessions or similar obligations.

Income taxes

The Company accounts for income taxes using the taxes payable method. Under this method, a provision is only made for taxes payable or recoverable in the current year. Income taxes payable/recoverable are measured using the income tax rates and laws established by taxation authorities and in effect at the balance sheet date.

 

5


2579951 Ontario Inc.

Notes to the Interim Consolidated Financial Statements

For the period ended March 31, 2021 and 2020

(Unaudited)

 

2.

Significant accounting policies (Continued from previous page)

 

Leases

A lease that transfers substantially all of the benefits and risks of ownership is classified as a capital lease. At the inception of a capital lease, an asset and a payment obligation is recorded at an amount equal to the lesser of the present value of the minimum lease payments and the property’s fair market value. Assets under capital leases are amortized using the declining balance method, over their estimated useful lives. All other leases are accounted for as operating leases and rental payments are expensed as incurred.

An arrangement contains a lease where the arrangement conveys a right to use the underlying tangible asset, and whereby its fulfillment is dependent on the use of the specific tangible asset. After the inception of the arrangement, a reassessment of whether the arrangement contains a lease is made only in the event that:

  -

there is a change in contractual terms;

  -

a renewal option is exercised or an extension is agreed upon by the parties to the arrangement;

  -

there is a change in the determination of whether the fulfillment of the arrangement is dependent on the use of the specific tangible asset; or

  -

there is a substantial physical change to the specified tangible asset.

Foreign currency translation

These financial statements have been presented in Canadian dollars, the principal currency of the Company’s operations.

Transaction amounts denominated in foreign currencies are translated into their Canadian dollar equivalents at exchange rates prevailing at the transaction dates. Carrying values of monetary assets and liabilities reflect the exchange rates at the balance sheet date. Gains and losses on translation or settlement are included in the determination of net earnings (loss) for the current period.

Long-lived assets

Long-lived assets consist of property, plant and equipment. Long-lived assets held for use are measured and amortized as described in the applicable accounting policies.

The Company performs impairment testing on long-lived assets held for use whenever events or changes in circumstances indicate that the carrying amount of an asset, or group of assets, may not be recoverable. The carrying amount of a long-lived asset is not recoverable if the carrying amount exceeds the sum of the undiscounted future cash flows from its use and disposal. If the carrying amount is not recoverable, impairment is then measured as the amount by which the asset’s carrying amount exceeds its fair value. Fair value is measured using discounted future cash flows. Any impairment is included in net earnings (loss) for the period.

Use of estimates

The preparation of financial statements in conformity with Canadian accounting standards for private enterprises requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period.

Accounts receivable are stated after evaluation as to their collectability and an appropriate allowance for doubtful accounts is provided where considered necessary. Provisions are made for slow moving and obsolete inventory, and for potential returns, allowance and price concessions on product sold. Amortization is based on the estimated useful lives of property, plant and equipment.

By their nature, these estimates are subject to measurement uncertainty, and the effect on the financial statements from changes in such estimates in future periods could be material. These estimates and assumptions are reviewed periodically and, as adjustments become necessary they are reported in earnings in the periods in which they become known.

Financial instruments

The Company recognizes its financial instruments when the Company becomes party to the contractual provisions of the financial instrument. All financial instruments are initially recorded at their fair value, including financial assets and liabilities originated and issued in a related party transaction with management. Financial assets and liabilities originated and issued in all other related party transactions are initially measured at their carrying or exchange amount in accordance with Section 3840 Related Party Transactions.

 

6


2579951 Ontario Inc.

Notes to the Interim Consolidated Financial Statements

For the period ended March 31, 2021 and 2020

(Unaudited)

 

2.

Significant accounting policies (Continued from previous page)

Financial instruments (Continued from previous page)

 

At initial recognition, the Company may irrevocably elect to subsequently measure any financial instrument at fair value. The Company has not made such an election during the period.

Transaction costs and financing fees directly attributable to the origination, acquisition, issuance or assumption of financial instruments subsequently measured at fair value are immediately recognized in net earnings (loss). Conversely, transaction costs and financing fees are added to the carrying amount for those financial instruments subsequently measured at cost or amortized cost.

 

3.

Inventory

 

     March 31
2021
     December 31
2020
 

Packaging materials

     9,552,491        4,571,980  

Cannabis plants

     1,812,457        1,833,898  

Bulk cannabis flower

     10,214,097        12,489,460  

Bulk cannabis extracts

     4,964,932        3,218,154  

Finished goods

     4,762,805        4,678,890  
     31,306,782        26,792,382  

The cost of inventories recognized as an expense and included in cost of sales amounted to $10,279,719 (March 31, 2020 – $8,228,063).

Included in cost of sales is amortization of production equipment of $3,069,742 (March 31, 2020 - $1,708,721).

 

4.

Receivable from shareholder

The balance due from the shareholder is unsecured, non-interest bearing and due on demand.

 

7


2579951 Ontario Inc.

Notes to the Interim Consolidated Financial Statements

For the period ended March 31, 2021 and 2020

(Unaudited)

 

5.

Property, plant and equipment

 

     Cost      Accumulated
amortization
     March 31
2021
Net book
value
     December 31
2020
Net book
value
 

Land and land improvements

     5,342,316        —          5,342,316        5,337,750  

Buildings

     61,226,893        9,036,892        52,190,001        52,106,153  

Automotive

     330,327        102,712        227,615        127,836  

Computer equipment

     1,795,158        1,402,256        392,902        425,424  

Computer software

     4,013,623        3,659,593        354,030        479,073  

Equipment

     36,389,087        9,874,708        26,514,379        25,189,288  

Fences

     21,187        11,133        10,054        10,312  

Furniture and fixtures

     316,282        84,807        231,475        247,401  

Office equipment

     151,511        38,351        113,160        114,416  

Machinery and equipment

     386,226        280,445        105,781        98,877  
     109,972,610        24,490,897        85,481,713        84,136,530  

Deposits included in the consolidated balance sheet represent deposits placed for certain property, plant and equipment to be used in the Company’s production operations, which has not been delivered as of March 31, 2021. Additional commitments relating to these items is disclosed in Note 10.

 

6.

Advances from related parties

 

     March 31
2021
     December 31
2020
 

2516576 Ontario Inc. (controlling shareholder)

     115,843,448        115,847,648  

Minority shareholders

     1,060        1,060  

Member of immediate family of minority shareholders

     390,500        367,250  
     116,235,008        116,215,958  

Amounts owing to the above related parties are unsecured, non-interest bearing and due on demand.

 

7.

Share capital

Authorized

Unlimited number of common shares

 

     March 31
2021
   December 31
2020

Issued

 

Common shares

     

100 Common shares

     48      48

 

8


2579951 Ontario Inc.

Notes to the Interim Consolidated Financial Statements

For the period ended March 31, 2021 and 2020

(Unaudited)

 

8.

Revenue

The Company earns revenues from sales to medical patients (“medical”) and through provincial distributors for the recreational market (“recreational”). The revenue before excise taxes recognized by major category is as follows:

 

     3 Months
Ended
March 31
2021
     3 Months
Ended
March 31
2020
 

Revenue

     

Medical

     1,610,210        1,078,589  

Recreational

     33,428,158        11,972,611  

Returns and allowances

     (1,121,304      (56,925

Revenue before excise taxes

     33,917,064        12,994,275  

 

9.

Income taxes

The reconciliation of the Company’s effective income tax expense is as follows:

 

     3 Months
Ended
March 31
2021
     3 Months
Ended
March 31
2020
 

Expected tax expense (recovery)

     1,677,760        (372,565

Increase (decrease) in income tax expense resulting from:

     

Impact of difference between amortization for accounting purposes and CCA taken in the period

     265,433        (542,168

Intercompany charges capitalized for tax purposes

     (1,095,847      2,151,701  

Non-deductible expenses

     4,787        2,972  

Impact of tax loss carried forward against period taxable income

     377,867        (630,274

Actual tax expense

     1,230,000        609,666  

 

10.

Commitments

The Company has entered into various lease agreements with estimated minimum annual payments as follows:

 

2021

     154,451  

2022

     210,000  

2023

     210,000  

2024

     210,000  

2025

     210,000  

Thereafter, to 2029

     390,000  
     1,384,451  

During the period, the Company signed various agreement to purchase items of manufacturing equipment. As at March 31, 2021, outstanding commitments for manufacturing equipment were $16,112,812.

 

9


2579951 Ontario Inc.

Notes to the Interim Consolidated Financial Statements

For the period ended March 31, 2021 and 2020

(Unaudited)

 

11.

Financial instruments

The Company, as part of its operations, carries a number of financial instruments. It is management’s opinion that the Company is not exposed to significant interest, currency, credit, liquidity or other price risks arising from these financial instruments except as otherwise disclosed.

Credit concentration

For the three months ended March 31, 2021, 3 customers (March 31, 2020 – 3) accounted for 89% ( March 31, 2020 – 92%) of revenues before excise duties and as at March 31, 2020, 3 customers (December 31, 2020 – 3) accounted for 94% (December 31, 2020 – 97%) of the accounts receivable. The Company believes that there is no unusual exposure associated with the collection of these receivables as the customers are government agencies that distribute cannabis in their respective provinces.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company’s objective is to have sufficient liquidity to meet its liabilities from due. The Company monitors cash balances and cash flows generated from operations to meet its requirements. The Company is exposed to liquidity risk relating to its trade and other payables and advances from related parties which are due on demand.

 

12.

Subsequent events

On May 28, 2021, HEXO Corp. announced that it has entered into a definitive share purchase agreement to acquire all the outstanding shares of the Company for a purchase price of $925 million payable in cash and through the issuance of common shares of HEXO Corp. (the “Transaction”). The Transaction is subject to certain customary adjustments, closing conditions, applicable regulatory approvals, and HEXO Corp. shareholder approval. The close date of the Transaction is not determinable as of the date of these financial statements. As part of the Transaction and related customary adjustments, the parties have agreed that the balance owing to the controlling shareholder 2516576 Ontario Inc., as disclosed in Note 6, will be settled in full on close of the Transaction. Accordingly, the balance owing to 2516576 Ontario Inc. has been classified as a current liability in advances from related parties in the consolidated balance sheet.

On May 14, 2021, 2579951 Ontario Inc. was amalgamated with its parent company, 2516576 Ontario Inc., to form 5048963 Ontario Inc. (the “Company”).

 

10


2579951 Ontario Inc.

Notes to the Interim Consolidated Financial Statements

For the period ended March 31, 2021 and 2020

(Unaudited)

 

13.

ASPE to International Financial Reporting Standards Reconciliation

As discussed in Note 12, the Company entered into a definitive share purchase agreement on May 28, 2021 to sell all of the outstanding shares of the Company to HEXO Corp. The Company has presented an ASPE to International Financial Reporting Standards (“IFRS”) reconciliation for the statement of earnings (loss), balance sheet and a description of the impact of each adjustment for each period presented. The tables below quantify the significant differences on the Company’s net earnings between ASPE and IFRS as at and for the 3 month periods ended March 31, 2021 and 2020 with descriptions thereto of such differences.

 

            Notes     

Three
Months
ended March

31, 2021

    

Three
Months
ended March

31, 2020

 

Net income (loss) after tax under ASPE

           6,913,624        (2,015,572

IFRS Adjustments

           

Variable consideration adjustment to gross revenue

        (i)        (278,998      (218,260

Realized fair value amounts on inventory sold

        (ii)        (15,472,095      (3,561,756

Unrealized gain on biological asset transformation

        (ii)        20,832,187        13,953,043  

Reversal of cost of sales

        (iii)        25,000        25,000  

Depreciation on right-of-use assets

        (iii)        (62,323      (62,323

Interest expense on lease liability

        (iii)        (36,925      (36,928

Reversal of rent expense

        (iii)        35,792        37,347  

Deferred income tax expense

        (iv)        (3,048,337      (1,589,577
     

 

 

    

 

 

    

 

 

 

Net and comprehensive income under IFRS

           8,907,925        6,530,974  
     

 

 

    

 

 

    

 

 

 

 

     Notes     As reported
under ASPE
     Adjustments      As reported
under IFRS
 

As at March 31, 2021

          

Inventory

     (ii)       31,306,782        52,366,927        83,673,709  

Biological assets

     (ii)       —          11,401,324        11,401,324  

Right-of-use assets, net

     (iii)       —          1,674,846        1,674,846  

Trade and other payables

     (iii)       6,172,256        (135,000      6,037,256  

Current lease liability

     (iii)       —          230,716        230,716  

Non-current lease liability

     (iii)       —          2,000,225        2,000,225  

Provisions

     (i), (iii)       —          520,212        520,212  

Deferred tax liability

     (iv)       —          17,623,787        17,623,787  

Retained earnings

     (i),(ii),(iii),(iv)       17,141,863        45,203,157        62,345,020  
          
     Notes     As reported
under ASPE
     Adjustments      As reported
under IFRS
 

As at December 31, 2020

          

Inventory

     (ii)       26,792,382        49,309,456        76,101,838  

Biological assets

     (ii)       —          9,098,703        9,098,703  

Right-of-use assets, net

     (iii)       —          1,737,168        1,737,168  

Trade and other payables

     (iii)       9,407,837        (120,000      9,287,837  

Current lease liability

     (iii)       —          238,650        238,650  

Non-current lease liability

     (iii)       —          2,001,156        2,001,156  

Provisions

     (i), (iii)       —          405,071        405,071  

Deferred tax liability

     (iv)       —          14,575,450        14,575,450  

Retained earnings

     (i),(ii),(iii),(iv)       10,828,239        43,045,000        53,873,239  

 

11


(i) Under IFRS, an adjustment is required to record the constraint on variable consideration resulting from the markdown / price reductions arrangements with customers.

(ii) Under IFRS, an adjustment is required to record biological assets at fair value less cost to sell. Further, biological assets are transferred to inventory at fair value less cost to sell. An adjustment is made to recognize inventory at cost which is the fair value less cost of sell at the point where it transferred from biological assets. The following represent the key assumptions used in the determination of the fair value of the biological assets:

Weighted average selling price (per gram) - $3.60 (December 31, 2020 - $3.18)

Yield per plant (dried bud and trim) - 1,143 grams (December 31, 2020 - 1,144 grams)

Stage of growth - 51% (December 31, 2020 - 43%)

Attrition rate - 1% (December 31, 2020 - 1%)

(iii) Under IFRS, an adjustment is required to record right-of-use assets and lease liabilities for items leased. After initial recognition, IFRS requires the discounted lease liability to be accreted to the full liability amount and associated interest expense is recognized. In preparing the estimate for the value of the lease liability, management has determined a range of incremental borrowing rates attributable to underlying leases to be 2.28% - 6.84%. Depreciation expense is recognized on the right-of use assets over the lease term or the non-cancellable lease term ranging from 2 - 21 years. Additionally, an adjustment for lease restitution costs is also required to be recognized under IFRS as a provision.

(iv) Under ASPE, the Company uses the taxes payable method of accounting for income taxes. Under IFRS, the Company is required to recognize both current and deferred taxes. Deferred tax has been recognized on any temporary differences between the carrying amounts of assets and liabilities and the corresponding tax bases used in the computation of taxable earnings. Deferred tax assets and liabilities have been measured at the tax rates that are expected to apply in the period when the asset is realized, and the liability is settled. Deferred tax assets are recognized to the extent future recovery is probable. Deferred tax assets have been reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.

 

12


SCHEDULE D

(See attached)


HEXO Corp.

Unaudited pro forma condensed consolidated financial statements

As at April 30, 2021 and for the nine months ended April 30, 2021 and for the year ended July 31, 2020

 

1


UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at April 30, 2021

(In thousands of Canadian dollars)

 

 
    

HEXO Corp.

April 30, 2021

    

Redecan Group
March 31, 2021

Note 8

     Pro Forma
Adjustments
    Note    

Pro Forma
Consolidated

April 30, 2021

 

ASSETS

            

Current assets

            

Cash and cash equivalents

     81,038        2,812        384,096       5     67,946  
           (400,000     6b  

Restricted funds

     32,551        —          —           32,551  

Trade receivables

     19,049        14,708        —           33,757  

Commodity taxes recoverable and other receivables

     10,202        1,533        —           11,735  

Prepaid expenses—current

     4,386        5,656        —           10,042  

Inventory

     95,223        83,673        16,327       6c     195,223  

Biological assets

     9,222        11,401        —           20,623  

Receivable from shareholders

     —          118        —           118  
  

 

 

    

 

 

    

 

 

     

 

 

 

Total current assets

     251,671        119,901        423         371,995  

Non-current assets

            

Property, plant and equipment

     280,183        86,838        13,162       6d ), 6e)      380,183  

Intangible assets

     16,412        319        99,681       6f     116,412  

Convertible debenture receivable

     20,246        —          —           20,246  

Investment in associate and joint ventures

     73,379        —          —           73,379  

Lease receivable

     3,795        —          —           3,795  

License and prepaid royalty

     —          —          —           —    

Long-term investments

     4,402        —          —           4,402  

Prepaid expenses

     3,101        —          —           3,101  

Deposits

     —          4,796        —           4,796  

Goodwill

     —          —          749,026       6g     749,026  
  

 

 

    

 

 

    

 

 

     

 

 

 

Total assets

     653,189        211,854        862,292         1,727,335  
  

 

 

    

 

 

    

 

 

     

 

 

 

 

2


UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at April 30, 2021

(In thousands of Canadian dollars)

 

 
    

HEXO Corp.

April 30, 2021

    

Redecan Group
March 31, 2021

Note 8

     Pro Forma
Adjustments
    Note    

Pro Forma
Consolidated

April 30, 2021

 

LIABILITIES

            

Current Liabilities

            

Accounts payable and accrued liabilities

     42,968        6,037        67,285       6h     116,290  

Excise taxes payable

     4,315        —          —           4,315  

Government remittances payable

     —          2,657        —           2,657  

Advances from related parties – current

     —          116,235        —           116,235  

Warrant liabilities

     13,037        —          —           13,037  

Lease liability

     4,659        231        —           4,890  

Term loan

     —          —          —           —    

Onerous contract

     4,763        —          —           4,763  

Income taxes payable

     —          3,605        —           3,605  
  

 

 

    

 

 

    

 

 

     

 

 

 

Total current liabilities

     69,742        128,765        67,285         265,792  

Non-current liabilities

            

Deferred tax liability

     —          17,624        82,376       6i     100,000  

Lease liability

     22,566        2,000        —           24,566  

Advances from related parties

     —          —          —           —    

Convertible debentures

     31,951        —          384,096       5     416,047  

Other long-term liabilities

     1,805        520        —           2,325  
  

 

 

    

 

 

    

 

 

     

 

 

 

Total liabilities

     126,064        148,909        533,757         808,730  

Shareholders’ equity

     527,125        62,945        (62,945     6a     918,605  
           458,765       6b  
           (67,285     6h  
  

 

 

    

 

 

    

 

 

     

 

 

 

Total liabilities and shareholders’ equity

     653,189        211,854        862,292         1,727,335  
  

 

 

    

 

 

    

 

 

     

 

 

 

See accompanying notes

 

3


UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF NET EARNINGS (LOSS)

For the nine months ended April 30, 2021

(In thousands of Canadian dollars except per share amounts)

 

 
    

HEXO Corp.

April 30, 2021

   

Redecan Group
March 31, 2021

Note 8

    Pro Forma
Adjustments
    Note    

Pro Forma
Consolidated

April 30, 2021

 

Revenue from sale of goods

     120,059       98,147       —           218,206  

Excise taxes

     (35,219     (27,539     —           (62,758
  

 

 

   

 

 

   

 

 

     

 

 

 

Net revenue from sale of goods

     84,840       70,608       —           155,448  

Ancillary revenue

     168       —         —           168  
  

 

 

   

 

 

   

 

 

     

 

 

 

Net revenue

     85,008       70,608       —           155,616  

Cost of goods sold

     57,391       29,910       (773     6d     86,528  
  

 

 

   

 

 

   

 

 

     

 

 

 

Gross profit before fair value adjustments

     27,617       40,698       773         69,088  

Realized fair value amounts on inventory sold

     17,619       72,209       —           89,828  

Unrealized gain on changes in fair value of biological assets

     (35,616     (115,454     —           (151,070
  

 

 

   

 

 

   

 

 

     

 

 

 

Gross profit

     45,614       83,943       773         130,330  

Operating expenses

          

Selling, general and administrative

     39,039       15,886       —           54,925  

Marketing and promotion

     6,682       1,638       —           8,320  

Share-based compensation

     10,904       —         —           10,904  

Research and development

     2,901       —         —           2,901  

Depreciation of property, plant and equipment

     4,369       1,153       195       6d     5,755  
         38       6e  

Amortization of intangible assets

     1,043       55       1,445       6f     2,543  

Restructuring costs

     1,721       —         —           1,721  

Impairment of property, plant and equipment

     881       626       —           1,507  

Impairment of intangible assets

     —         —         —           —    

Impairment of goodwill

     —         —         —           —    

Recognition of onerous contract

     —         —         —           —    

Disposal of long-lived assets

     1,294       —         —           1,294  

Loss on disposal of property, plant and equipment

     45       —         —           45  

Acquisition and transactions

     2,307       —         (447     6h     1,860  
  

 

 

   

 

 

   

 

 

     

 

 

 
     71,186       19,358       1,231         91,775  
  

 

 

   

 

 

   

 

 

     

 

 

 

Earnings (loss) from Operations

     (25,572     64,585       (458       38,555  

Finance expense, net

     (7,311     (161     (42,951     5     (50,423

Non-operating expense, net

     (12,864     (148     —           (13,012
  

 

 

   

 

 

   

 

 

     

 

 

 

Earnings (loss) and comprehensive income (loss) attributable to shareholders before tax

     (45,747     64,276       (43,409       (24,880

Provision for income taxes

     —         (4,185     272       6i     (3,913

Income tax payable

     —         (12,672     —           (12,672
  

 

 

   

 

 

   

 

 

     

 

 

 

Other comprehensive income

          

Foreign currency translation

     3       —         —           3  
  

 

 

   

 

 

   

 

 

     

 

 

 

Net earnings (loss) and comprehensive income (loss)

     (45,744     47,419       (43,137       (41,462
  

 

 

   

 

 

   

 

 

     

 

 

 

Comprehensive income (loss) attributable to:

          

Shareholders of Hexo Corp

     (45,744     47,419       (43,137       (41,462

Non-controlling interest

     —         —         —           —    
  

 

 

   

 

 

   

 

 

     

 

 

 
     (45,744     47,419       (43,137       (41,462
  

 

 

   

 

 

   

 

 

     

 

 

 

 

4


UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF NET EARNINGS (LOSS)

For the nine months ended April 30, 2021

(In thousands of Canadian dollars except per share amounts)

 

 
    

HEXO Corp.

April 30, 2021

   

Redecan Group
March 31, 2021

Note 8

     Pro Forma
Adjustments
     Note     

Pro Forma
Consolidated

April 30, 2021

 

Basic net loss per common share

   $ (0.38           7      $ (0.22

Diluted net loss per common share

   $ (0.38           7      $ (0.22

Basic weighted average number of outstanding shares

     121,749,456             7        191,470,572  

Diluted weighted average number of outstanding shares

     121,749,456             7        191,470,572  

See accompanying notes

 

5


UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF NET EARNINGS (LOSS)

For the year ended July 31, 2020

(In thousands of Canadian dollars except per share amounts)

 

    

HEXO Corp.

July 31, 2020

Note 3

   

Redecan Group
September 30, 2020

Note 8

    Pro Forma
Adjustments
    Note    

Pro Forma
Consolidated

July 31, 2020

 

Revenue from sale of goods

     110,149       74,478       —           184,627  

Excise taxes

     (29,598     (20,285     —           (49,883
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue from sale of goods

     80,551       54,193       —           134,744  

Ancillary revenue

     233       —         —           233  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     80,784       54,193       —           134,977  

Cost of goods sold

     127,205       27,922       1,535       6d     156,662  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross (loss) / profit before fair value adjustments

     (46,421     26,271       (1,535       (21,685

Realized fair value amounts on inventory sold

     40,910       47,465       —           88,375  

Unrealized gain on changes in fair value of biological assets

     (29,356     (102,715     —           (132,071
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross (loss) / profit

     (57,975     81,521       (1,535       22,011  

Operating expenses

          

Selling, general and administrative

     52,793       14,127       —           66,920  

Marketing and promotion

     12,474       421       —           12,895  

Share-based compensation

     25,790       —         —           25,790  

Research and development

     4,639       —         —           4,639  

Depreciation of property, plant and equipment

     6,072       1,557       240       6d     7,920  
         51       6e  

Amortization of intangible assets

     3,939       235       1,765       6f     5,939  

Restructuring costs

     4,767       —         —           4,767  

Impairment of property, plant and equipment

     79,418       —         —           79,418  

Impairment of intangible assets

     108,189       —         —           108,189  

Impairment of goodwill

     111,877       —         —           111,877  

Recognition of onerous contract

     4,763       —         —           4,763  

Disposal of long-lived assets

     —         —         —           —    

Loss on disposal of property, plant and equipment

     3,855       —         —           3,855  

Acquisition and transactions

     —         —         —           —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     418,576       16,340       2,056         436,972  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from operations

     (476,551     65,181       (3,591       (414,961

Finance income (expense), net

     (8,141     (114     (60,853     5     (69,108

Non-operating income (expense), net

     (67,820     (2     —           (67,822
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) and comprehensive income (loss) attributable to shareholders before tax

     (552,512     65,065       (64,444       (551,891

Provision for income taxes

     —         (2,377     1,241       6i     (1,136

Income tax recovery (payable)

     6,023       (15,528     —           (9,505
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income

          

Foreign currency translation

     —         —         —           —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) and comprehensive income (loss)

     (546,489     47,160       (63,203       (562,532
  

 

 

   

 

 

   

 

 

     

 

 

 

Comprehensive income (loss) attributable to:

          

Shareholders of HEXO Corp.

     (546,489     47,160       (63,203       (562,532

Non-controlling interest

     —         —         —           —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     (546,489     47,160       (63,203       (562,532
  

 

 

   

 

 

   

 

 

     

 

 

 

 

6


UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF NET EARNINGS (LOSS)

For the year ended July 31, 2020

(In thousands of Canadian dollars except per share amounts)

 

    

HEXO Corp.

July 31, 2020

Note 3

    

Redecan Group
September 30, 2020

Note 8

     Pro Forma
Adjustments
     Note     

Pro Forma
Consolidated

July 31, 2020

 

Basic net loss per common share

   $ (1.77)              7      $ (1.48)  

Diluted net loss per common share

   $ (1.77)              7      $ (1.48)  

Basic weighted average number of outstanding shares

     309,504,695              7        379,225,811  

Diluted weighted average number of outstanding shares

     309,504,695              7        379,225,811  

See accompanying notes

 

7


1.

Description of the Transaction

On May 28, 2021 HEXO Corp. (“HEXO” or the “Company”) entered into a definitive share purchase agreement (the “Share Purchase Agreement) to acquire the Redecan Group comprised of 2526356 Ontario Inc., 2579951 Ontario Inc. and 9037136 Canada Inc. (“Redecan”). Under the terms of the Share Purchase Agreement and based on the closing price of common shares on July 6, 2021, the consideration payable is estimated to be $858,765, payable in (i) $400,000 of cash, and (ii) an aggregate of 69,721,116 common shares to be issued by the Company. The Acquisition is expected to close in Q1 of the Company’s 2022 fiscal year, subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals. HEXO has raised debt financing which the Company will use to finance the cash consideration payable in connection with the Acquisition.

These unaudited pro forma condensed consolidated financial statements present the impact of the following transactions and have been prepared on the basis described in Note 2, Basis of Preparation:

 

  a)

The Acquisition as described in Note 4, The Acquisition

 

  b)

The incurrence of indebtedness under the senior secured convertible notes (the “Notes”) with proceeds of $384,096 (USD$312,655), as described in Note 5, Senior Secured Convertible Notes

 

2.

Basis of Preparation

The Company’s unaudited pro forma condensed consolidated statement of financial position as at April 30, 2021 and the unaudited pro forma condensed consolidated statements of net earnings (loss) for the nine months ended April 30, 2021 and the year ended July 31, 2020 have been prepared by management for the purpose of presenting the impact of the Acquisition, as described herein. Although the Acquisition had not closed as of the date of these pro forma financial statements, the unaudited pro forma condensed consolidated statement of financial position includes the effect of these transactions as if they had occurred on April 30, 2021. The unaudited pro forma condensed consolidated statement of net earnings (loss) for the nine months ended April 30, 2021 and the year ended July 31, 2020 give effect to these transactions as if they had occurred on August 1, 2019. These unaudited pro forma condensed consolidated financial statements also reflect and give effect to the issuance of the Notes, which were issued in order to finance the cash component of the purchase price of the Acquisition as described in Note 5—Senior Secured Convertible Notes, however, they do not reflect or assume the issuance of any number of HEXO common shares upon conversion, redemption or exchange of any Notes.

The accounting policies used in the preparation of these unaudited pro forma condensed consolidated financial statements, incorporate the significant accounting policies used by HEXO Corp. for the respective periods in the Company’s consolidated financial statements filed with or furnished to, as applicable, the Canadian and U.S. securities regulatory authorities. The unaudited pro forma condensed consolidated financial statements include all adjustments necessary for the fair presentation of these unaudited pro forma financial statements.

Pro forma adjustments reflected in these unaudited pro forma condensed consolidated financial statements are based on items that are factually supportable, directly attributable to the Acquisition for which there are firm commitments, and are expected to have a continuing impact on these unaudited pro forma condensed consolidated financial statements for which completed financial effects are objectively determinable.

All dollar amounts, except for per share information, or unless otherwise specified are expressed in thousands of Canadian dollars (“CAD” or “$”), which is the presentation currency of HEXO Corp.

These unaudited pro forma condensed consolidated financial statements have been prepared using the following information:

 

   

The unaudited condensed interim consolidated statement of financial position of HEXO as at April 30, 2021 and the unaudited condensed interim consolidated statement of net loss and comprehensive loss for the nine-month period ended April 30, 2021 have been extracted from the unaudited condensed interim consolidated financial statements prepared in accordance with International Accounting Standards 34 (“IAS 34”) as issued by the IASB.

 

8


   

The consolidated statements of net loss and comprehensive loss of HEXO for the year ended July 31, 2020 has been extracted from the Company’s audited consolidated financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) as filed with or furnished to the Canadian and U.S. securities regulatory authorities.

 

   

The unaudited condensed interim consolidated balance sheet of Redecan as at March 31, 2021 and the unaudited condensed interim consolidated statements of earnings (loss) for the three months ended March 31, 2021 have been extracted from Redecan’s unaudited condensed interim consolidated financial statements prepared in accordance with Canadian accounting standards for private enterprises (“ASPE”) as issued by the Accounting Standards Board in Canada (“AcSB”).

 

   

The unaudited condensed interim consolidated statement of net earnings (loss) of Redecan for the nine month period ended March 31, 2021 has been derived from the audited consolidated statement of earnings (loss) of Redecan for the year ended December 31, 2020 prepared in accordance with ASPE as issued by the AcSB. The unaudited interim statement of earnings (loss) of Redecan for the nine-month period ended March 31, 2021 has been constructed by subtracting the unaudited financial information from the accounting records for the six-month period ended June 30, 2020 from the audited income statement for the year ended December 31, 2020 and adding the unaudited financial information extracted from the unaudited condensed interim consolidated statements of statements of earnings (loss) for the three months ended March 31, 2021. Adjustments have been made to Redecan’s historical financial information to conform with HEXO’s IFRS accounting policies (see Note 8, Adjustments to the Historical Financial Statements of Redecan).

 

   

The unaudited condensed consolidated statement of net earnings (loss) of Redecan for the twelve months ended September 30, 2020 has been derived from the unaudited consolidated statement of earnings (loss) of Redecan for the year ended December 31, 2019 prepared in accordance with ASPE and the unaudited financial information is derived from the accounting records of Redecan for the nine-month periods ended September 30, 2020 and September 30, 2019. The unaudited condensed consolidated statement of net earnings (loss) of Redecan for the twelve-month period ended September 30, 2020 has been constructed by subtracting the unaudited financial information from the accounting records for the nine-month period ended September 30, 2019 from the unaudited consolidated statement of earnings (loss) for the year ended December 31, 2019 and adding the unaudited financial information derived from the accounting records for the nine-month period ended September 30, 2020. Adjustments have been made to Redecan’s historical financial information to conform with HEXO’s IFRS accounting policies (see Note 8, Adjustments to the Historical Financial Statements of Redecan).

These unaudited pro forma condensed consolidated financial statements, including the notes thereto, should be read in conjunction with HEXO’s historical financial statements, and respective Management’s Discussion and Analysis of financial condition and results of operations as filed with or furnished to, as applicable, the Canadian and U.S. securities regulatory authorities and Redecan’s historical financial statements.

These unaudited pro forma condensed consolidated financial statements are based on assumptions and adjustments that are described in the accompanying notes. The unaudited pro forma condensed consolidated financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the Acquisition. The unaudited pro forma condensed consolidated financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of operations in future periods or the results that actually would have been realized if HEXO and the acquired company (being the Redecan Group) had been a consolidated company during the specified periods.

The application of the acquisition method of accounting depends on certain valuations and other studies that have yet to be completed. Accordingly, the pro forma adjustments are preliminary, subject to further revisions as additional information becomes available and additional analyses are performed and have been made solely for the purposes of providing unaudited pro forma condensed consolidated financial statements. Differences between these preliminary estimates and the final acquisition accounting will occur and these differences could have a material impact on the accompanying unaudited pro forma condensed consolidated financial statements and the consolidated company’s

 

9


future earnings and financial position. Further, differences between the preliminary and final amounts will likely occur as a result of changes in the fair value of HEXO’s common shares to determine the actual purchase consideration as well as the actual amount of cash used in Redecan’s operations, and other changes in assets and liabilities.

 

3.

Presentation Reclassification Adjustments to HEXO’s Condensed Consolidated Statement of Net Earnings (Loss) for the Year ended July 31, 2020

For the nine months ended April 30, 2021, HEXO simplified its presentation for the condensed interim consolidated statements of net loss and comprehensive loss. For consistency between the unaudited pro forma condensed consolidated statement of net earnings (loss) for the nine months ended April 30, 2021 and the year ended July 31, 2020, the following presentation reclassification adjustments which had a $nil impact on net earnings (loss) and comprehensive income (loss) were made to HEXO’s condensed consolidated statement of net earnings (loss) for the year ended July 31, 2020:

HEXO CONDENSED CONSOLIDATED STATEMENT OF NET EARNINGS (LOSS)

For the year ended July 31, 2020

(In thousands of Canadian dollars except per share amounts)

 

     As reported
HEXO Corp.

July 31, 2020
     Presentation
reclassification
     Adjusted
Presentation
 

Revenue from sale of goods

     110,149        —          110,149  

Excise taxes

     (29,598      —          (29,598
  

 

 

    

 

 

    

 

 

 

Net revenue from sale of goods

     80,551        —          80,551  

Ancillary revenue

     233        —          233  
  

 

 

    

 

 

    

 

 

 

Net revenue

     80,784        —          80,784  

Cost of goods sold

     127,205        —          127,205  
  

 

 

    

 

 

    

 

 

 

Gross loss before fair value adjustments

     (46,421      —          (46,421

Realized fair value amounts on inventory sold

     40,910        —          40,910  

Unrealized gain on changes in fair value of biological assets

     (29,356      —          (29,356
  

 

 

    

 

 

    

 

 

 

Gross loss

     (57,975         (57,975

Operating expenses

        

Selling, general and administrative

     52,793        —          52,793  

Marketing and promotion

     12,474        —          12,474  

Share-based compensation

     25,790        —          25,790  

Research and development

     4,639        —          4,639  

Depreciation of property, plant and equipment

     6,072        —          6,072  

Amortization of intangible assets

     3,939        —          3,939  

Restructuring costs

     4,767        —          4,767  

Impairment of property, plant and equipment

     79,418        —          79,418  

Impairment of intangible assets

     108,189        —          108,189  

Impairment of goodwill

     111,877        —          111,877  

Recognition of onerous contract

     —          4,763        4,763  

Loss on onerous contract

     4,763        (4,763      —    

Loss on disposal of property, plant and equipment

     3,855        —          3,855  
  

 

 

    

 

 

    

 

 

 
     418,576        —          418,576  
  

 

 

    

 

 

    

 

 

 

Loss from operations

     (476,551      —          (476,551
  

 

 

    

 

 

    

 

 

 

Finance expense, net

     —          (8,141      (8,141

Non-operating expense, net

     —          (67,820      (67,820

Revaluation of financial instruments gain

     6,533        (6,533      —    

Share of loss from investment in associate and joint ventures

     (6,331      6,331        —    

 

10


Loss on induced conversion of debentures

     (54,283      54,283        —    

Realized loss on convertible debentures receivable

     (4,806      4,806        —    

Unrealized loss on investments

     (12,880      12,880        —    

Realized gain on investments

     24        (24      —    

Foreign exchange gain

     1,392        (1,392      —    

Interest and financing expenses

     (10,043      10,043        —    

Interest income

     1,902        (1,902      —    

Other income

     2,531        (2,531      —    
  

 

 

    

 

 

    

 

 

 

Loss and comprehensive loss attributable to shareholders before tax

     (552,512      —          (552,512

Income tax recovery

     6,023        —          6,023  
  

 

 

    

 

 

    

 

 

 

Other comprehensive income

        

Foreign currency translation

     —          —          —    
  

 

 

    

 

 

    

 

 

 

Net loss and comprehensive loss

     (546,489      —          (546,489
  

 

 

    

 

 

    

 

 

 

Comprehensive loss attributable to:

        

Shareholders of HEXO Corp.

     (546,489      —          (546,489

Non-controlling interest

     —          —          —    
  

 

 

    

 

 

    

 

 

 
     (546,489      —          (546,489
  

 

 

    

 

 

    

 

 

 

 

4.

The Acquisition

Upon completion of the Acquisition, HEXO will pay cash and issue common shares of its capital to the shareholders of Redecan in consideration and exchange for all of the issued and outstanding shares of the Redecan Group. The purchase consideration is approximately $400,000 of cash and 69,721,116 common shares with an estimated value of approximately $458,765 for total consideration of $858,765. The cash consideration component is subject to adjustments on and following the closing date for working capital target surplus (deficit).

The estimated purchase price for Redecan is based on the closing price of HEXO common shares on July 6, 2021. The requirement to base the final purchase price on the share price as of the closing date could result in a purchase price that is materially different (either higher or lower) from that assumed in these unaudited pro forma condensed consolidated financial statements and the purchase price included in these pro forma financial statements should not be taken to represent what the actual consideration transferred will be when the Acquisition is completed. The actual purchase price will fluctuate until the effective date of the Acquisition and the final valuation could differ significantly from the current estimate.

 

Number of HEXO common shares to be issued

     69,721,116  
  

 

 

 

HEXO share price per share(i)

   $ 6.58  
  

 

 

 

Equity portion of purchase price

   $ 458,765  

Cash consideration

   $ 400,000  
  

 

 

 

Purchase price

   $ 858,765  
  

 

 

 

 

  (i)

HEXO’s Canadian dollar closing share price of $6.58 from the TSX on July 6, 2021.

The following table shows the effect of an increase (decrease) in the purchase price and the change in timing of the close of the Acquisition on the purchase price and goodwill:

 

     Purchase Price
$
     Goodwill
$
 

As presented in the pro forma combined results

   $ 858,765        749,026  
  

 

 

    

 

 

 

15% increase in common share price

   $ 927,580        817,841  

15% decrease in common share price

   $ 789,950        680,211  
  

 

 

    

 

 

 

As of the date of these pro forma financial statements, the Company’s detailed identification and valuation exercise of Redecan’s net assets has not yet significantly begun. Therefore, the Company has prepared a preliminary estimate of

 

11


the fair market values of the assets to be acquired and the liabilities assumed under the Acquisition using high level approximations of a consistent $100,000 value for inventory, property, plant and equipment, identifiable intangible assets and the deferred tax liability. Pro forma adjustments have been made to eliminate Redecan’s historical carrying values and to reflect the allocation of the preliminary purchase price where there is a difference between the carrying value and fair value.

The final purchase price allocation will be determined when the Company has completed the detailed valuations and necessary calculations. The final purchase price allocation could differ materially from the preliminary purchase price allocation and may include changes in fair values of property, plant and equipment, changes in allocation to intangibles assets such as brands, trade names, technology, licenses and customer relationships as well as goodwill.

The following table summarizes the allocation of the preliminary purchase price:

 

Net identifiable assets acquired    As at April 30, 2021
$
 

Financial assets

     29,623  

Inventory

     100,000  

Biological assets

     11,401  

Property, plant and equipment

     100,000  

Identifiable intangible assets

     100,000  

Financial liabilities

     (124,929

Lease liability

     (2,231

Income taxes payable

     (3,605

Deferred tax liability

     (100,000

Other long-term liabilities

     (520
  

 

 

 

Total net identifiable assets

     109,739  

Goodwill

     749,026  
  

 

 

 

Purchase price

     858,765  
  

 

 

 

 

5.

Senior Secured Convertible Notes

On May 27, 2021, the Company closed an offering of US$360 million aggregate principal amount of senior secured convertible notes (the “Notes”) directly to an institutional purchaser and certain of its affiliates or related funds.

The Notes were sold at a purchase price of US$327.6 million, or approximately 91.0% of their principal amount. The Notes mature on May 1, 2023. Subject to certain limitations, the Notes will be convertible into freely tradable common shares of the Company at the option of the holder and, subject to conditions and limitations, at the option of the Company. If not previously converted, all principal repayments of the Notes will be made at a price equal to 110% of the principal amount of the Notes being repaid. The Notes do not bear interest except upon the occurrence of an event of default. The Notes were issued in registered form, without coupons, under a trust indenture.

The unaudited pro forma condensed consolidated statement of financial position has been adjusted to reflect an increase in cash and Notes of $384,096 (US$312,655), net of estimated transaction costs of $18,360 (USD$14,945). The following table shows the interest expense incurred on the new Notes assuming such Notes had been issued on the first day of the periods presented therein:

 

     For the nine
months ended
April 30, 2021

$
     For the year ended
July 31, 2020
$
 

Finance income (expense), net(i)

     (42,951      (60,853

 

(i)

Although the notes do not carry an interest rate (other than after the occurrence of an event of default), the above interest expense (presented as net finance expense) represents for accounting purposes, the implied finance expense attributable to the difference between the discounted price at which the Notes were originally issued and the principal amount outstanding under the Notes.

 

12


6.

Pro Forma Adjustments and Assumptions for the Acquisition of Redecan

The unaudited pro forma condensed consolidated financial statements include the following pro forma assumptions and adjustments:

 

  a)

Equity

This pro forma adjustment eliminates Redecan’s historical equity of $62,945.

 

  b)

Purchase Price

Records the purchase price consideration, which is cash of $400,000 and the fair value of the equity interests of $458,765 to be issued by HEXO to acquire Redecan (Note 4, The Acquisition).

 

  c)

Inventory

Increases Redecan’s inventory to an estimated fair value of approximately $100,000, an increase of $16,327 from the carrying value. The fair value was determined based on the estimated selling price of the inventory, less the manufacturing processing and selling costs and a normal profit margin on those manufacturing and selling efforts. After the Acquisition the $16,327 increase in inventory value will increase cost of goods sold over approximately 12 months as the inventory is sold. This increase is not reflected in the unaudited pro forma condensed consolidated statements of net earnings (loss) because it does not have a continuing impact.

 

  d)

Property, plant and equipment

Increases Redecan’s property, plant and equipment to an estimated fair value of approximately $100,000, an overall increase of $13,162 from the carrying value. The estimated useful lives (excluding land) range from 3 to 20 years. The Company capitalizes a portion of depreciation and amortization to biological assets and inventory and the increase in property, plant and equipment value will increase cost of goods sold. The estimated adjustment to depreciation of property, plant and equipment and cost of goods sold related to the acquired property, plant and equipment calculated on a straight line basis was $195 and $(773) respectively for the nine months ended April 30, 2021 and $240 and $1,535 respectively for the twelve months ended July 31, 2020.

 

  e)

Leases

Included in property, plant and equipment is $1,675 related to right-of-use lease assets. The carrying value has been adjusted to the corresponding carrying value of the lease liability of $2,231, resulting in a pro forma increase of $556. The corresponding impact to depreciation of property, plant and equipment related to the acquired leases was $38 for the nine months ended April 30, 2021 and $51 for the twelve months ended July 31, 2020.

 

  f)

Intangible assets

Reflects the fair value adjustment to intangible assets of approximately $100,000, an overall increase of $99,681 from the carrying value. Intangible assets currently identified as part of the preliminary valuation study for intangible assets include brands, trade names, technology, licenses and customer relationships. The preliminary valuation used an income approach that forecasts the expected future cash flows. The midpoint of the estimated range of fair values was used.

The estimated value fair of the currently identifiable intangible assets has been equally allocated across the assets due to the limitation of information held at the very early stages of the identification and valuation assessment. The estimated fair value and useful lives of the acquired intangibles are as follows

 

     Estimated Fair Value
$
     Estimated useful life
(years)
 

Domain names

     20,000        10 years  

Health Canada licenses

     20,000        20 years  

Software

     20,000        3 to 5 years  

Patents

     20,000        20 years  

Brands

     20,000        Indefinite  
  

 

 

    
     100,000     
  

 

 

    

After the Acquisition, the estimated adjustment to amortization expense related to the acquired intangibles calculated on a straight line basis was $1,445 for the nine months ended April 30, 2021 and $1,765 for the twelve months ended July 31, 2020.

 

13


The preliminary estimates of fair value and estimated useful lives will likely differ from the final amounts after completing the valuation study, and the difference could have a material effect on the pro forma financial statements. A 15% change in the estimated fair value of intangible assets would cause a corresponding increase or decrease of $15,000 in the balance of goodwill. A 15% change would also cause the amortization expense in the unaudited pro forma condensed consolidated statement of earnings (loss) for the nine months ended April 30, 2021 and for the twelve months ended July 31. 2020 to increase or decrease by approximately $256 and $341 respectively (assumes a weighted average useful life of 11 years).

 

  g)

Goodwill

Recognizes goodwill of $749,026 to reflect the purchase price allocation described in Note 4, The Acquisition.

 

  h)

Transaction costs

Represents the elimination of non-recurring transaction costs incurred and recognized during the nine month period ended April 30, 2021 of $447 that are directly related to the acquisition of Redecan. This amount has been removed from the pro forma statement of earnings and loss because it is non-recurring in nature and would not reflect expense of the combined entity on an ongoing basis.

Transaction costs that are directly attributable to the acquisition of Redecan and factually supportable but have not yet been expensed in HEXO or Redecan’s historical income statements or accrued in the balance sheet are reflected as an increase to accounts payable and accrued liabilities and a corresponding decrease in shareholder’s equity of $67,285 on the unaudited pro forma condensed consolidated statement of financial position.

 

  i)

Income taxes For the purpose of the pro forma adjustments included in these unaudited pro forma condensed consolidated financial statements, the following tax rates were applied:

 

   

HEXO’s effective income tax rate was nil% for the nine months ended April 30, 2021 and for the year ended July 31, 2020. The effective tax rate is different than the statutory rate primarily due to the non-recognition of deferred tax assets for unused tax losses. As a result, no tax is recorded on the pro-forma adjustment of acquisition related costs incurred by HEXO.

 

   

Redecan’s effective income tax rates of 30.13% for the nine months ended April 30, 2021 and 34.57% for the year ended July 31, 2020 were used in determining a corresponding decrease in provision for income taxes of $272 and $1,241, respectively, as a result of adjustments to cost of goods sold, depreciation of property, plant and equipment and amortization of intangible assets.

 

   

The deferred tax liability of $100,000 (an overall increase of $82,376 from the carrying value) arising on the Acquisition is composed of the cumulative amount of tax applicable to temporary differences between the accounting and tax values of assets and liabilities related to the Acquisition. Deferred income tax assets and liabilities are measured at the tax rates expected to be in effect when these differences reverse.

 

7.

Pro Forma Earnings (Loss) Per Share

Basic and diluted net income or loss per share is calculated by dividing the net income or loss for the period by the pro forma weighted average numbers of common shares that would have been outstanding during the period using the treasury stock method. The weighted average number of common shares was determined by taking the historical weighted average number of common shares outstanding and adjusting for the shares issued under the Acquisition as follows:

 

     For the nine months
ended April 30, 2021
     For the year ended
July 31, 2020
 

Numerator

     

Numerator for basic and diluted earnings per common share—Pro forma net earnings(i)

   $ (41,462,000    $ (562,532,000

Denominator

     
  

 

 

    

 

 

 

Denominator for basic earnings per common share – weighted average number of common shares

     121,749,456        77,376,174  

Pro forma adjustment for newly-issued shares related to the Acquisition

     69,721,116        69,721,116  
  

 

 

    

 

 

 

 

14


     For the nine months
ended April 30, 2021
     For the year ended
July 31, 2020
 

Pro Forma denominator for basic earnings per common shares – weighted average common shares

     191,470,572        147,097,290  

Effect of dilutive securities

     40,750,951        165,862,789  
  

 

 

    

 

 

 

Pro forma denominator for diluted earnings per common shares – weighted average common shares

     232,221,523        312,960,079  

Pro forma basic earnings per common share

   $ (0.22    $ (3.82

Pro forma diluted earnings per common share

   $ (0.22    $ (3.82

 

(i)

For the purpose of this footnote, Pro forma net earnings is in whole dollars

The denominator figures for common shares reflect the 4:1 stock consolidation executed December 18, 2020

 

15


8.

Adjustments to the Historical Financial Statements of Redecan

The historical financial information of Redecan was prepared in accordance with ASPE as issued by the AcSB and presented in Canadian dollars. Redecan’s fiscal year end is December 31 and historical financial information was used to present pro forma financial statements based on the fiscal year end of HEXO being July 31.

The following tables present the conversion from ASPE to IFRS and shows the presentation and reclassification adjustments which had a $nil impact on the total assets, liabilities, shareholder’s equity and net earnings (loss) for the periods presented:

Redecan Adjusted Unaudited Condensed Consolidated Statement of Financial Position

 

         ASPE                       IFRS  
     As at March
31, 2021
     ASPE to
IFRS
differences
     Note 8     As at
March 31,
2021
     Presentation
reclassification
    Adjusted
Presentation
 

Assets

               

Current assets:

               

Cash and cash equivalents

     2,812        —            2,812          2,812    

Trade receivables

     14,708        —            14,708          14,708    

Government remittances receivable

     1,533        —            1,533        (1,533     —    

Commodity taxes recoverable and other receivables

     —          —            —          1,533       1,533    

Inventory

     31,306        52,367          (i     83,673          83,673    

Biological assets

     —          11,401          (i     11,401          11,401    

Prepaid expenses—current

     5,656        —            5,656          5,656    

Receivable from shareholders

     118        —            118          118    
  

 

 

    

 

 

      

 

 

    

 

 

   

 

 

 

Total current assets

     56,133        63,768            119,901        —         119,901    

Property and equipment

     85,482        —            85,482        1,356       86,838    

Intangible assets

     —          —            —          319       319    

Deposits

     4,796        —            4,796          4,796    

Right—  of—  use assets, net

     —          1,675          (ii     1,675        (1,675     —    
  

 

 

    

 

 

      

 

 

    

 

 

   

 

 

 

Total assets

     146,411        65,443            211,854        —         211,854    
  

 

 

    

 

 

      

 

 

    

 

 

   

 

 

 

Liabilities

               

Current liabilities

               

Trade and other payables

     6,172        (135)          (ii     6,037        (6,037     —    

Accounts payable and accrued liabilities

     —          —            —          6,037       6,037    

Government remittances payable

     2,657        —            2,657          2,657    

Lease liability

     —          231          (ii     231          231    

Income taxes payable

     3,605        —              3,605          3,605    

Advances from related parties

     116,235        —              116,235          116,235    
  

 

 

    

 

 

      

 

 

    

 

 

   

 

 

 

Total current liabilities

     128,669        96            128,765        —         128,765    

Lease liability

     —          2,000          (ii     2,000          2,000    

Provisions

     —          23          (ii     520        (520     —    
        497        (iii       

Advances from related parties

     —          —            —            —    

Deferred tax liability

     —          17,624          (iv     17,624          17,624    

Other long—  term liabilities

     —          —            —          520       520    

Total liabilities

     128,669        20,240            148,909        —         148,909    
  

 

 

    

 

 

      

 

 

    

 

 

   

 

 

 

Shareholders’ equity

     17,742        63,768          (i     62,945          62,945    
        (444)          (ii       
        (497)          (iii       
        (17,624)          (iv       

Total liabilities and shareholders’ equity

     146,411        65,443            211,854        —         211,854    
  

 

 

    

 

 

      

 

 

    

 

 

   

 

 

 

 

16


Redecan Adjusted Unaudited Condensed Consolidated Statement of Net Earnings—Interim

     ASPE                   IFRS  
     Year
ended
December 31,
2020
    Six
months
ended
June 30,
2020
    Three
months
ended
March 31,
2021
    Nine
months
ended
March 31,
2021
    ASPE to
IFRS
differences
     Note 8      Nine
months
ended
March 31,
2021
    Presentation
reclassification
     Nine  
months  
ended  
March 31,  
2021  
 

Revenue before returns and allowances

     107,296       38,140       35,038       104,194       (1,259)          (iii)        102,935       (102,935)        —    

Revenue from sale of goods

     —         —         —         —         —             —         98,147        98,147    

Returns and allowances

     (5,209     (1,542     (1,121     (4,788     —             (4,788     4,788        —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Revenue before excise taxes

     102,087       36,598       33,917       99,406       (1,259)             98,147       —          98,147    

Excise taxes

     (28,438)       (10,164)       (9,265)       (27,539)       —             (27,539)       —          (27,539)    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Net revenue

     73,649       26,434       24,652       71,867       (1,259)             70,608       —          70,608    

Cost of goods sold

     35,812       16,107       10,280       29,985       (75)          (ii)        29,910       —          29,910    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Gross (loss) / profit before fair value adjustments

     37,837       10,327       14,372       41,882       (1,184)             40,698       —          40,698    

Realized fair value amounts on inventory sold

     —         —         —         —         72,209          (i)        72,209       —          72,209    

Unrealized gain on changes in fair value of biological assets

     —         —         —         —         (115,454)          (i)        (115,454)       —          (115,454)    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Gross profit

     37,837       10,327       14,372       41,882       42,061             83,943       —          83,943    

Operating expenses

                            

Selling, general and administrative

     —         —         —         —         —             —         15,886        15,886    

Marketing and promotion

     —         —         —         —         —             —         1,638        1,638    

Advertising and promotion

     997       86       727       1,638       —             1,638       (1,638)        —    

Amortization

     1,304       661       379       1,022       186          (ii)        1,208       (1,208)        —    

Depreciation of property, plant and equipment

     —         —         —         —         —             —         1,153        1,153    

Amortization of intangible assets

     —         —         —         —         —             —         55        55    

Business taxes and licences

     2,149       873       673       1,949       —             1,949       (1,949)        —    

Consulting fees

     1,316       931       142       527       —             527       (527)        —    

Donations

     —         —         —         —         —             —         —          —    

Freight and logistics

     1,851       778       681       1,754       —             1,754       (1,754)        —    

Insurance

     811       304       276       783       —             783       (783)        —    

Interest and bank charges

     148       30       43       161       —             161       (161)        —    

Interest expense on lease liability

     —         —         —         —         111          (ii)        111       (111)        —    

Meals and entertainment

     119       59       25       85       —             85       (85)        —    

Office and general

     1,904       763       513       1,654       —             1,654       (1,654)        —    

Professional fees

     261       81       16       196       —             196       (196)        —    

Property tax

     101       102       54       53       —             53       (53)        —    

Rental

     152       76       37       113       (110)          (ii)        3       (3)        —    

Repairs and maintenance

     1,123       421       259       961       —             961       (961)        —    

Salaries, wages and benefits

     6,189       2,014       1,404       5,579       —             5,579       (5,579)        —    

Supplies

     2,738       1,339       832       2,231       —             2,231       (2,231)        —    

Impairment of property, plant and equipment

     589       —         37       626       —             626       —          626    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 
     21,752       8,518       6,098       19,332       187             19,519       (161)        19,358    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Earnings from operations

     16,085       1,809       8,274       22,550       41,874             64,424       161        64,585    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Finance expense, net

     —         —         —         —         —             —         (161)        (161)    

Non-operating expense, net

     —         —         —         —         —             —         (148)        (148)    

Earnings and comprehensive earnings attributable to shareholders before tax

     16,085       1,809       8,274       22,550       41,874             64,424       (148)        64,276    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Provision for income taxes

     (4,500)       (1,545)       (1,230)       (4,185)       —             (4,185)          (4,185)    

Deferred income tax expense

     —         —         —         —         (12,672)          (iv)        (12,672)       12,672        —    

Income tax payable

     —         —         —         —         —             —         (12,672)        (12,672)    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Other comprehensive income

                     

Foreign exchange gain (loss)

     37       55       (130)       (148)       —             (148)       148        —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Net earnings and comprehensive income

     11,622       319       6,914       18,217       29,202             47,419       —          47,419    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

 

17


Redecan Adjusted Unaudited Condensed Consolidated Statement of Net Earnings – Annual

 

     ASPE                 IFRS  
     Year
ended
December

31, 2019
    Nine
months
ended
September

30, 2020
    Nine
months
ended
September

30, 2019
    Twelve
months
ended
September

30, 2020
    ASPE to
IFRS
differences
    Note 8     Twelve
months
ended
September

30, 2020
    Presentation
reclassification
    Twelve
months
ended
September

30, 2020
 

Revenue before returns and allowances

     17,337       10,545       72,015       78,807       (367     (iii     78,440       (78,440     —    

Revenue from sale of goods

     —         —         —         —         —           —         74,478       74,478  

Returns and allowances

     (152     (121     (3,931     (3,962     —           (3,962     3,962       —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

Revenue before excise taxes

     17,185       10,424       68,084       74,845       (367       74,478       —         74,478  

Excise taxes

     (3,965     (2,575     (18,895     (20,285     —           (20,285     —         (20,285
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

Net revenue

     13,220       7,849       49,189       54,560       (367       54,193       —         54,193  

Cost of goods sold

     6,028       3,946       25,940       28,022       (100     (ii     27,922       —         27,922  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

Gross (loss) / profit before fair value adjustments

     7,192       3,903       23,249       26,538       (267       26,271       —         26,271  

Realized fair value amounts on inventory sold

     —         —         —         —         47,465       (i     47,465       —         47,465  

Unrealized gain on changes in fair value of biological assets

     —         —         —         —         (102,715     (i     (102,715     —         (102,715
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

Gross profit

     7,192       3,903       23,249       26,538       54,983         81,521       —         81,521  

Operating expenses

                  

Selling, general and administrative

     —         —         —         —         —           —         14,127       14,127  

Marketing and promotion

     —         —         —         —         —           —         421       421  

Advertising and promotion

     319       169       271       421       —           421       (421     —    

Amortization

     1,022       515       1,040       1,547       245       (ii     1,792       (1,792     —    

Depreciation of property, plant and equipment

     —         —         —         —         —           —         1,557       1,557  

Amortization of intangible assets

     —         —         —         —         —           —         235       235  

Business taxes and licences

     486       339       1,547       1,694       —           1,694       (1,694     —    

Consulting fees

     —         —         1,131       1,131       —           1,131       (1,131     —    

Donations

     2       1       —         1       —           1       (1     —    

Freight and logistics

     284       177       1,385       1,492       —           1,492       (1,492     —    

Insurance

     514       362       538       690       —           690       (690     —    

Interest and bank charges

     89       54       79       114       —           114       (114     —    

Interest expense on lease liability

     —         —         —         —         148       (ii     148       (148     —    

Meals and entertainment

     100       79       87       108       —           108       (108     —    

Office and general

     489       341       1,271       1,419       —           1,419       (1,419     —    

Professional fees

     174       142       168       200       —           200       (200     —    

Property tax

     64       —         102       166       —           166       (166     —    

Rental

     191       117       114       188       (214     (ii     (26     26       —    

Repairs and maintenance

     271       205       831       897       —           897       (897     —    

Salaries, wages and benefits

     2,420       1,739       3,265       3,946       —           3,946       (3,946     —    

Supplies

     727       574       2,108       2,261       —           2,261       (2,261     —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 
     7,152       4,814       13,937       16,275       179         16,454       (114     16,340  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

Earnings (loss) from operations

     40       (911     9,312       10,263       54,804         65,067       114       65,181  

Finance expense, net

     —         —         —         —         —           —         (114     (114

Non-operating expense, net

     —         —         —         —         —           —         (2     (2
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

Earnings (loss) and comprehensive income (loss) attributable to shareholders before tax

     40       (911     9,312       10,263       54,804         65,067       (2     65,065  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

Provision for income taxes

     (123     —         (2,254     (2,377     —           (2,377       (2,377

Deferred income tax expense

     —         —         —         —         (15,528     (iv     (15,528     15,528       —    

Income tax payable

     —         —         —         —         —           —         (15,528     (15,528
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

Other comprehensive income

                  

Foreign exchange gain (loss)

     44       14       (32     (2     —           (2     2       —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

Net earnings (loss) and comprehensive income (loss)

     (39     (897     7,026       7,884       39,276         47,160       —         47,160  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

 

   

 

 

   

 

 

 

 

18


IFRS differs in material respects in certain areas from ASPE. The following material adjustments have been made to reflect Redecan’s historical consolidated statement of earnings on an IFRS basis for the purposes of the unaudited pro forma financial information, these adjustments are before the reclassification adjustments:

 

i.

Biological assets and inventory

Cannabis plants are recognized as biological assets under IFRS. Under IFRS, biological assets are accounted for using the income approach at fair value less costs to sell and are revalued at each subsequent reporting date up to the point of harvest, which becomes the basis for the cost of inventories after harvest. Under IFRS, unrealized gains or losses arising from changes in fair value less cost to sell during the period are included in the statement of net earnings.

Inventory is valued at the lower of cost and net realizable value. Under ASPE, cannabis plants are recorded at the lower of cost and net realizable value. Cost is determined by the weighted average method, and includes purchase price of direct materials, direct labour and an allocation of certain overheads. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest date, which becomes the initial deemed cost of the inventory. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. The identified capitalized direct and indirect costs related to inventory are subsequently recorded within ‘cost of goods sold’ on the statement of net earnings at the time the product is sold, with the exclusion of realized fair value amounts on inventory sold which are recorded as a separate line within gross profit.

The following table shows the addition of the fair value adjustment to the cost basis of biological assets and inventory under ASPE to reflect the fair value of cannabis plants in accordance with IFRS and includes a corresponding impact to shareholder’s equity:

 

     As at March 31, 2021
$
 

Inventory

     52,367  

Biological assets

     11,401  

Shareholder’s equity

     63,768  

The following table reflects the addition of the changes in fair value recognized in the period of change within the unaudited condensed consolidated statement of net earnings for the nine months ended March 31, 2021:

 

     Year ended
December 31,
2020

$
     Six months
ended June 30,
2020

$
     Three months
ended March 31,
2021

$
     Nine months
ended March 31,
2021

$
 

Realized fair value amounts on inventory sold

     81,213        24,476        15,472        72,209  

Unrealized gain on changes in fair value of biological assets

     (122,237      (27,615      (20,832      (115,454

The following table reflects the addition of the changes in fair value recognized in the period of change within the unaudited condensed consolidated statement of net earnings for the twelve months ended September 30, 2020:

 

     Year ended
December 31,
2019

$
     Nine months
ended
September 30,
2019

$
     Nine months
ended
September 30,
2020

$
     Twelve months
ended
September 30,
2020

$
 

Realized fair value amounts on inventory sold

     6,014        3,499        44,950        47,465  

Unrealized gain on changes in fair value of biological assets

     (18,933      (8,574      (92,356      (102,715

 

ii.

Leases

For lessees, IFRS does not distinguish between operating and finance lease requirements and recognizes a right-of-use asset and lease liability at the commencement of all leases except short-term leases and leases of low value assets. To reflect the IFRS lease accounting requirements, the following adjustments were made to the unaudited condensed consolidated statement of financial position:

 

19


     As at March 31, 2021
$
 

Increase in right-of-use assets, net

     1,675  

Decrease in trade and other payables

     (135

Increase in current lease liability

     231  

Increase in non-current lease liability

     2,000  

Increase in provisions

     23  

Decrease in shareholders’ equity

     (444

To recognize the depreciation of the right-of-use assets and interest on lease liabilities in the unaudited condensed consolidated statement of net earnings for the nine months ended March 31, 2021, the following adjustments were made:

 

     Year ended
December 31,
2020

$
     Six months
ended June 30,
2020

$
     Three months
ended March 31,
2021

$
     Nine months
ended March 31,
2021

$
 

Cost of goods sold

     (100      (50      (25      (75

Amortization

     249        125        62        186  

Interest expense on lease liability

     148        74        37        111  

Rental expense

     (149      (75      (36      (110

To recognize the depreciation of the right-of-use assets and interest on lease liabilities in the unaudited condensed consolidated statement of net earnings for the twelve months ended September 30, 2020, the following adjustments were made:

 

     Year ended
December 31,
2019

$
     Nine months
ended
September 30,
2019

$
     Nine months
ended
September 30,
2020

$
     Twelve months
ended
September 30,
2020

$
 

Cost of goods sold

     (75      (50      (75      (100

Amortization

     198        140        187        245  

Interest expense on lease liability

     146        109        111        148  

Rental expense

     (190      (88      (112      (214

 

iii.

Revenue

IFRS applies a five step control based model for revenue recognition, whereas ASPE recognizes revenue once the risk and rewards have been transferred to the customer. Under IFRS, variable consideration in customer contracts can result in consideration paid or payable to customers if a distinct good or service is received from the customer as a reduction of the transaction price. As at March 31, 2021, to reflect the impact of variable consideration an increase of $497 was recognized as a contract liability with a corresponding adjustment to shareholder’s equity.

The impact of the variable consideration from discount features resulted in the following adjustments on the unaudited condensed consolidated statement of net earnings for the nine months ended March 31, 2021:

 

     Year ended
December 31,
2020

$
     Six months
ended June 30,
2020

$
     Three months
ended March 31,
2021

$
     Nine months
ended March 31,
2021

$
 

Decrease to revenue before returns and allowances

     (250      730        (279      (1,259

The impact of the variable consideration from discount features resulted in the following adjustments on the unaudited condensed consolidated statement of net earnings for the twelve months ended September 30, 2020:

 

20


     Year ended
December 31,
2019

$
     Nine months
ended
September 30,
2019

$
     Nine months
ended
September 30,
2020

$
     Twelve months
ended
September 30,
2020

$
 

Decrease to revenue before returns and allowances

     (113             (254      (367

 

iv.

Income taxes

IFRS requires an entity to recognize both current and deferred taxes whereas ASPE permits the taxes payable method. Deferred tax is required to be recognized on any temporary differences between the carrying amount of assts and liabilities and the corresponding tax bases used in the calculation of taxable earnings. Deferred tax aessets and liabilities have been measured at the tax rates that are expected to apply in the period when the asset is realized, and the liability is settled. Deferred tax assets are recognized to the extent future recovery is probable. Deferred tax assets have been reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.

As at March 31, 2021, a deferred tax liability of $17,624 was recognized with a corresponding adjustment to shareholder’s equity.

The impact of the applying deferred tax accounting resulted in the following adjustment on the unaudited condensed consolidated statement of net earnings for the nine months ended March 31, 2021:

 

     Year ended
December 31,
2020

$
     Six months
ended June 30,
2020

$
     Three months
ended March 31,

2021
$
     Nine months
ended March 31,
2021

$
 

Deferred income tax expense

     (10,619      (995      (3,048      (12,672

The impact of the applying deferred tax accounting resulted in the following adjustment on the unaudited condensed consolidated statement of net earnings for the twelve months ended September 30, 2020:

 

     Year ended
December 31,
2019

$
     Nine months
ended
September 30,
2019

$
     Nine months
ended
September 30,
2020

$
     Twelve months
ended
September 30,
2020

$
 

Deferred income tax expense

     (3,956      (1,781      (13,353      (15,528

 

21